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Aptamers are synthetic, single stranded nucleic acids that bind specifically to the 
target protein. Aptamers have many potential uses including therapeutic and diagnostic 
applications. Most aptamers are identified through standard SELEX (Systematic 
Evolution of Ligands by EXponential enrichment) procedures that include a starting pool 
of nucleic acids with a region of random nucleotides flanked by fixed sequences. A main 
disadvantage of the traditional SELEX is the potential for the fixed sequences to “bias” 
the selection by interacting with nucleotides in the random region of the oligonucleotide. 
I developed a novel primer-free SELEX method for isolating single strand 30 nt DNA 
aptamers from a random sequence pool for HIV reverse transcriptase (HIV-RT), in which 
selection occurs in the absence of any flanking, fixed nucleotides. Selected aptamers 
bound ~10-20 fold tighter than starting material to HIV-RT. The selected aptamer (PF1) 
  
contained a motif of four diguanosine repeats. PF1 was compared to two classes of HIV-
RT aptamers: a G-quadruplex aptamer (R1T family) from Michalowski et al., Nuc. Acids 
Res. 2008, and a primer-template aptamer developed by our lab (37 NT SELEX, 
DeStefano and Nair, Oligonucleotides 2008). PF1 was an effective inhibitor of HIV-RT 
in vitro and bound to RT about as tightly as a full primer-template. Both the R1T and 
37NT SELEX were more potent HIV-RT inhibitors. This may be due in part to their large 
size. Circular dichroism spectroscopy indicated that PF1 does not form a G-quadruplex, 
while the R1T, consistent with previous results, is a parallel G-quadruplex.  
The effect of the primer-template aptamer on HIV inhibition in cell culture was 
also studied. Low micromolar concentrations of aptamer in the absence of a transfection 
agent inhibited replication in Jurkat cells without significant cellular toxicity. However 
constructs with similar structure also inhibit HIV replication leading us to conclude that 
aptamer blockage of replication may be due to alteration of cellular pathways.  
In addition to the possible contribution in developing novel nucleic acid-based 
HIV inhibitors, aptamer selection experiments can also shed light on how RT interacts 
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Chapter 1: Introduction 
1.1 Discovery of HIV and AIDS   
Human immunodeficiency virus (HIV) is a lentivirus (lenti, “slow (growth)” in 
Latin) in the Retroviridae family. The Retroviridae (retrovirus) family utilizes reverse 
transcriptase in a reverse flow of genetic information, which the enzyme converts the 
viral RNA into DNA during replication. HIV is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS), where the virus targets and decimates T helper 
cells and macrophages in humans. AIDS is defined by an individual testing positive for 
HIV antibodies or positive for HIV by PCR, and their CD4+ T-lymphocyte count in blood 
is below 200 cells/µl. The infected individual also exhibits one or more of a collection of 
26 known opportunistic infections and AIDS-related symptoms (150). 
HIV was co-discovered by two lab groups in 1983. Françoise Barré-Sinoussi and 
Luc Montagnier et al. at the Pasteur Institute in Paris isolated the virus from the lymph 
nodes of a patient with opportunistic infections (pathogens which normally do not cause 
diseases in a healthy individual). The virus was named “lymphadenopathy-associated 
virus“, or LAV (14). Robert Gallo’s group at the U.S. National Institutes of Health used 
samples from Montagnier to purify and characterize the virus, which they named human 
T cell lymphotropic virus III (HTLV III) (54). In 1986, the Human Retrovirus Sub-
committee of the International Committee on the Taxonomy of Viruses decided on the 





1.2 AIDS Epidemiology and HIV Classification 
Since the first recording of clinical cases of HIV/AIDS in 1981, AIDS has 
claimed more than 33 million lives. Even though the number of deaths each year is 
steadily declining, about 1.8 million people died from AIDS-related diseases in 2009, 
including 260,000 children (175). As of 2009, ~33.3 million people were living with 
HIV/AIDS, including 15.6 million women and 2.5 million children (175). HIV is a 
bloodborne pathogen which spreads through direct contact of bodily fluids via 
unprotected sex and contact with blood and/or blood products. The high-risk populations 
include workers in the sex industry (prostitutes, pornographic film actors, etc.) and 
intravenous drug users that practice needle sharing. Although blood transfusion patients 
were previously in this group, current blood screening practices have greatly decreased 
the risk of contracting HIV by transfusion. In the USA, homosexual men remain a high 
risk group due to the high level of HIV infection. HIV positive mothers can pass the 
disease to their newborn infants during childbirth or through breastfeeding. Health care 
and research workers are also at risk of coming into contact with HIV-contaminated 
samples, although the risk of contracting HIV remains low. 
HIV has been defined as a quasispecies, which is a population of closely related 
yet genetically distinct viruses (182). The rapid divergence of HIV is due to several 
factors, including the large number of infected individuals, vigorous recombination, and 
an error-prone polymerase. These genetically distinct viruses are subjected to continuous 
genetic variation, selection, and competition (47). There are two types of HIV (Figure 1-
1): HIV type 1 (HIV-1) and type 2 (HIV-2), which share 60% homology between their 






Figure 1-1: Classification of the human immunodeficiency virus. HIV-1 and Group M 
(Major) are the predominant types in each division respectively. Note that subtypes E and 
I are not included: subtype E are now known as CRF01_AE (see above), while subtype I 
is a CRF consisting of subtypes A, G, H, K and other unclassified regions. Figure 




cases are mainly found in West and Central Africa. HIV-1 is more infectious and easier 
to transmit than HIV-2. There are four groups of HIV-1: M (Major), O (Outlier), N (Non-
M non-O) and the recently discovered P (Pending) (134). Group M is the predominant 
group which causes over 90% of the worldwide HIV-1 infections. Group M is further 
divided into ten subtypes, or clades (10). The different subtypes can undergo 
recombination during infection to produce “recombinant form” (RF) viruses. Infectious 
RFs that circulate and become persistent within a population are dubbed “circulating 
recombinant forms” (CRFs), which are considered one of the ten subtypes. The most 
epidemiologically abundant CRF, CRF01_AE (formerly misclassified as subtype E), 
constitutes almost 5% of total HIV infections worldwide (138) . 
 
1.3 HIV Pathogenesis 
HIV infection is marked by the detection of HIV antibodies, and a gradual 
decrease in total T cell counts - especially of CD4+ T cells, which is the primary target of 
HIV. A healthy, uninfected individual has CD4+ T cell counts between 800 to 1200/µl of 
blood. On average, the development of AIDS occurs about 8 to 12 years after initial 
infection with HIV in untreated hosts. Infection can be divided into three stages as listed 
below (Figure 1-2):  
1. Acute (primary) infection: acute infection occurs 2-4 weeks after exposure to 
HIV, and lasts between a few days to ten weeks (91). The HIV viral load increase 
significantly, while the number of circulating CD4+ T cells in the blood drops to 
about 50% of the original level (from ~ 1200 cells/µl to ~ 600 cells/µl) (60). HIV-






Figure 1-2: A generalized graph of the levels of HIV RNA copies (viral load) and 
CD4
+
 T cell counts during the different stages of HIV disease progression. The viral 
load level is indicated in red, and the CD4+ T cell count is in blue. The average clinical 
latency period is between 8-12 years without antiretroviral drug treatment, though the 
HIV disease progression pattern for each individual depends on their age and health. 




among other non-specific symptoms. Some HIV-infected individual may be 
asymptomatic during the acute infection stage. The increase in viruses induces 
production of antibodies against HIV, and a rise in CD8+ T cell mediated immune 
response. The slower progression rate to AIDS is linked to a stronger CD8+ T cell 
response in individuals (128). The CD8+ T cell response and the antibody-
mediated response lower the amount of virus in the blood, and allow the CD4+ T 
cells to rise back to near normal levels (~ 800 cells/µl). These host responses do 
not eliminate the virus completely. 
2. Chronic (secondary) infection: the CD4+ T cell count in the individual’s blood 
stream remains somewhat stable for several months to years without antiretroviral 
therapy intervention. Under the definition from the Centers for Disease Control 
and Prevention (CDC), clinical latency is referred as HIV infection stage 1, where 
the CD4+ T cell count is between 500-1200 cells/µl in a patient’s blood. During 
the chronic infection period, approximately 10 billion viruses are produced per 
day. HIV RNA levels remain low and constant, as the host immune system is still 
functioning to target the infected cells and viruses. Later in the chronic infection a 
patient may enter Stage 2 HIV infection where the CD4+ T cell count drops to 
200-499/µl, but no AIDS-defining conditions exist. However, other symptoms 
(exp. Herpes infections, increased cancer risk, papillomavirus infections etc.) 
usually appear in the HIV-positive individual at this stage. 
3. AIDS: the stage where the HIV-infected patient shows a highly decimated CD4+ 
T cell count and the appearance of various opportunistic infections. The onset of 




blood is below (200 cells/µl), and the patient is susceptible to AIDS-defining 
opportunistic infections (OIs) and neoplasms. A wide range of microorganisms 
that a healthy individual’s immune system can normally combat become 
opportunistic pathogens in an AIDS patient. Some of the common OIs associated 
with AIDS are Pneumocystis carinii pneumonia (PCP), candidiasis, toxoplasma 
encephalitis, cytomegalovirus infections, as well as others. About 40% of AIDS 
patients develop neoplasms and cancers such as Kaposi’s sarcoma, Burkitt’s 
lymphoma, B cell lymphomas and cervical cancer (from human papillomavirus). 
AIDS also causes neurological and psychiatric effects: AIDS dementia complex 
(ADC), multifocal leukoencephalopathy and various myelopathies are observed in 
later stages of AIDS. 
 
1.4 HIV Structural Characteristics 
HIV is a complex, spherical virus about 80-100 nm in diameter (Figure 1-2). All 
retroviruses, including HIV, contain a lipid-based envelope, which is derived from the 
host cell outer membrane lipid bilayer. The virus encodes the surface glycoproteins 
gp120, and a transmembrane gp41 glycoprotein (13).  
The inner membrane of the lipid envelope is lined by a ~17 kDa matrix protein 
(MA, p17). The genetic material of the virus is enclosed by a bullet-shaped core (32), 
made of the 24 kD capsid protein (CA, p24). The two copies of the single-stranded RNA 
genome are coated with the nucleocapsid protein (NC, p7), a nucleic acid chaperone that 
aids destabilization of secondary structures and facilitates template annealing, reverse 






Figure 1-3: A schematic diagram of human immunodeficiency virus (HIV) and its 
structural characteristics. HIV is an enveloped virus containing the surface 
glycoproteins gp120 and gp41. The lipid envelope is lined by the matrix protein (MA). 
The capsid (CA) protein forms a bullet-shaped core enclosing two copies of single-
stranded plus sense RNA genome. Both copies of the RNA are coated with nucleocapsid 
protein (NC). The capsid core contains copies of the viral enzymes: such as reverse 






  The capsid core also contains the three HIV key enzymes: reverse transcriptase, 
protease and integrase. Reverse transciptase (RT) is a hetereodimer with 51 and 66 kD 
subunits. Protease (PR, ~10 kD) is the enzyme responsible for cleavage of the HIV 
polyproteins. Integrase (IN, ~ 32 kD) facilitates proviral DNA insertion into the host 
DNA genome. Other HIV regulatory proteins, such as virion infectivity factor (Vif), viral 
protein R (Vpr), and Negative Factor (Nef) are also present in the virion (see Section 1.5 
for details on their functions). 
 
1.5 HIV Genetic Organization and Protein Functions 
The HIV genome consists of two copies of plus sense single-stranded linear RNA, 
each of which is approximately 9.1 kb long. The two (nearly) identical copies of the RNA 
strands are linked together by a non-covalent bond at the 5′ end to form a dimer. HIV is 
considered to be a pseudodiploid virus: only one of the two RNA genomes will be 
converted into the proviral double-stranded DNA for integration into the host DNA 
genome (74). The two genomes contribute to the genetic recombination in the virus, and 
enhance the survival rate of the virus if one of the RNA genome is damaged (74). The 
HIV three major genes are gag, pol and env (Figure 1-4). The gag codes for structural 
proteins (matrix, capsid, and nucleocapsid), while pol encodes the three key enzymes: 
reverse transcriptase (RT), integrase and protease; env is responsible for production of 
surface and transmembrane glycoproteins (gp120 and gp41, respectively). Table 1-1 lists 
the protein products of the nine genes in HIV, and the protein functions in the HIV life 
cycle (161). The protein products in HIV are generated by translation of full length 




Viral protein No. of Protein 
copies / virion 
Viral protein function in HIV 
replication 
Capsid, CA (p24Gag) ~5000 - involves in core structure and  
  assembly of the virion 
Matrix, MA (p17Gag) ~5000 - targets Gag to the plasma membrane   
  for viral assembly 
- promotes Env incorporation 
- viral post-entry events 
Nucleocapsid, NC (p7Gag) ~5000 - genomic RNA packaging 
- facilitates reverse transcription 
- RNA chaperone activity 
- assembly of virion 
p6Gag ~5000 - promotes virion budding 
Reverse Transcriptase, RT ~250 - proviral DNA synthesis from  
  RNA or DNA templates 
- RNase H cleavage of RNA 
Integrase, IN ~250  
 
- insertion of proviral cDNA into host  
  DNA  
Protease, PR ~250 - proteolytic cleavage of Gag and  
  Gag-Pol polyproteins 
Surface Glycoprotein, SU 
(gp120Env) 
4-35 trimers - host cell surface receptor binding 




4-35 trimers - fusion peptide aids membrane 
  fusion and entry of the virion 
Virion Infectivity Factor, 
Vif 
1-150 - APOBEC3G/F suppression 
 
Viral Protein R, Vpr ~700 - enhances post-entry infectivity 
- G2/M cell-cycle arrest 
trans-Activator of 
Transcription, Tat 
N/A - activates viral transcription  
  elongation by interacting with TAR 
Regulator of Expression of 
Virion Proteins, Rev 
N/A - Enhances nuclear export of viral    
  RNAs with introns in viral RNAs 
Viral Protein U, Vpu N/A - CD4/MHC downregulation 
- viral release 
Negative Factor, Nef Yes, cleaved by 
PR 
- CD4/MHC downregulation 
- T-cell activation 
- blocks apoptosis 
- pathogenecity determinant 
- enhances viral infectivity 
 
Table 1-1: A list of HIV proteins and the protein functions in the HIV life cycle. 






Figure 1-4: Organization of the HIV genome, and the encoded protein products. The 
positions of the nine genes are relative. The products resulting from gag, pol and env are 
described. Note that the Gag-Pol polyprotein is produced as one single protein due to the 
-1 frameshifting mechanism for the pol gene to be translated after gag (23). Tat and rev 
are both shown upstream and downstream of env, since splicing within the env gene is 
required to complete the coding of the tat and rev proteins. See Table 1-1 for the HIV 





mRNA (all other proteins), and cleavage of the polyproteins after translation (Figure 1-4). 
 
1.6 HIV-1 Life Cycle 
The HIV-1 life cycle is divided into six main steps (Figure 1-5): 
1. Viral Entry: HIV entry relies on the binding of the viral surface glycoprotein (SU, 
gp120) to the CD4 receptors, a type of glycoprotein expressed on the surface of T 
helper (CD4+) cells or macrophages. In addition to the CD4 receptor, the virus 
requires a chemokine co-receptor on the host cell to attain viral entry. HIV gp120 
either attaches on the CXCR4 (X4) receptor of CD4+ cells, or the CCR5 (R5) 
receptor found on macrophages. The binding of the gp120 to both the CD4 
receptor and the chemokine receptor induces a conformational change in the HIV 
transmembrane glycoprotein (gp41) (147). The gp41 unfolds its hydrophobic 
domain into the host cell membrane (146), which facilitates the fusion of the viral 
and host cell membranes (97). 
2. Reverse Transcription: After entry into the cell, the HIV capsid core undergoes 
structural changes and reverse transcription begins in this modified core structure. 
Although the viral RNA genome contains translatable information, HIV 
undergoes an intermediary double-stranded DNA stage by reverse transcription 
(166). Reverse transcription is the conversion of the single-stranded RNA genome 
into a double-stranded DNA. HIV-RT can both utilize RNA and DNA as 
templates for DNA synthesis. The minus sense DNA strand is first synthesized 




RNA template strand. The minus sense DNA is used as a template for the plus 
sense DNA strand (see section 1.7 for detailed steps).  
3. Proviral DNA Integration: The enzyme integrase facilitates insertion of the 
proviral DNA into the host genome (25). The integration location on the host 
DNA is random, although active transcription sites seems to be favored (36, 152). 
A “central DNA flap” aids nuclear import of the viral double-stranded DNA into 
the host cell nucleus (9, 189). The proviral DNA is cleaved by HIV integrase. 
HIV integrase creates “sticky ends” by removing two nucleotides from the 3′ ends 
of the viral DNA strands. The processed proviral DNA is inserted into the host 
DNA sequence. After integration, the host cell repairs the DNA, thus completing 
the process of incorporating the viral DNA into the host genome. The viral DNA 
is stable as a provirus within the host cell and the virus can utilize host RNA and 
protein synthesis machinery for transcription and splicing of the mRNA and 
translation of viral proteins. 
4. Viral mRNA synthesis and processing: The proviral DNA initiates RNA 
transcription at the promoter site in the long terminal repeats (LTRs). Even 
though HIV contains a single-strand RNA genome, it cannot be directly used as a 
template for translation due to the lack of a 7-methylated-G cap at the 5′ end (32). 
The newly transcribed viral mRNA undergoes the 5′ capping, while the 3′ end 
undergoes polyadenylation directed by the LTRs.  
5. Viral protein synthesis: HIV protein synthesis occurs at the host cell cytoplasm, 
after the processed or full length viral mRNA is exported from the nucleus. 




Later, as the REV (which is made from a multiple spliced mRNA) concentration 
builds up, export of singly spliced and unspliced mRNAs increases (135). The 
gag-pol portion of the HIV-1 is transcribed as a single gene from unspliced 
mRNA. The Pol portion of the Gag-Pol polyprotein contains the viral enzymes 
(reverse transcriptase, protease and integrase) that are essential for HIV-1 
replication and viral infectivity. Normally, only the gag portion is translated into 
the Gag protein product, however about 5-10% of the translation produces the 
Gag-Pol polyprotein (23, 79). The generation of the Gag-Pol relies on a 
programmed -1 ribosomal frameshift, which requires a “slippery site” which 
allows the simultaneous “slippage” of the two ribosome-bound tRNAs from the 0 
reading frame to -1 frame. This step allows the tRNA to bypass the stop codon of 
the gag to continue translating the pol gene (79). The frequency of HIV-1 
programmed -1 frameshifting is carefully controlled to achieve the precise ratio 
for the Gag:Gag-Pol proteins. Even a subtle modification of the Gag:Gag-Pol 
ratio can have significant effects on viral infectivity. Overexpression of the Gag 
protein produces non-infectious particles due to the lack of viral enzymes (26, 
45). The overproduction of the Gag-Pol polyprotein can produce excess protease 
in the cell, which inhibits the HIV assembly of structural proteins into complete 
virions (29, 93, 129). When the Gag:Gag-Pol ratios in cells were changed from 
20:1 to 20:21, the genomic RNA dimerization was progressively inhibited, and 
viral infectivity was reduced by about 1000-fold (153). The polyproteins 
translated from gag, gag-pol and env are cleaved by proteases. The Gag and Pol 




is processed by host proteases to produce the surface gp120 and transmembrane 
gp41 proteins. 
6. Assembly, budding and maturation of HIV: During assembly, the two single-
stranded viral RNA genomes, structural proteins and viral enzymes are directed 
toward the cell surface of the host. The viral components are directed towards the 
lipid rafts at the host cell membrane, which provides a platform for viral assembly 
(181). The HIV-1 Gag or Gag-Pol precursor proteins (Pr55Gag, and Pr165Gag-Pol, 
respectively) associate with the host cell membrane by a myristic acid domain and 
a highly basic region in the matrix portion of the Pr55Gag. Previous studies have 
showed that the matrix portion in Gag also interacts with the cytoplasmic tail in 
the gp41 transmembrane protein (181). The Pr55Gag proteins also interact with 
each other (known as the Gag-Gag interaction) and multimerizes. During 
multimerization the Env protein and other host proteins are incorporated into the 
budding virion. The highly multimerized curvature on the cell surface, with the 
aid of the ESCRT facilitates the virus to “pinch off” from the host membrane and 
exit the host cell. The maturation of HIV occurs during the late assembly stage or 
during/immediately after viral budding. Maturation occurs when the HIV 
polyproteins (for example, Gag-Pol polyprotein) are cleaved by HIV protease to 
produce functional protein units. Thus, blocking polyprotein cleavage 
(maturation) provides a good target for HIV-1 drug therapy (193). The matured, 







Figure 1-5: A schematic of the HIV-1 life cycle. HIV enters to the host cell by attaching 
onto the CD4 and CXCR4/CCR5 co-receptors on the host cell surface. After the fusion of 
the viral and host cell membrane, the virion enters into the cell and releases its core into 
the cytoplasm. Reverse transcription takes place to convert the single-stranded RNA 
genome into a double-stranded DNA. The proviral DNA then integrates into the host 
genome to form a provirus. The virus utilizes the host cell RNA polymerase II to 
transcribe the viral mRNA for protein synthesis, as well as new genomic RNA for new 
viruses. The genomic RNA, structural proteins and enzymetic polyproteins are assembled 
at the host cell membrane. The immature virions exit the cell surface and viral maturation 
completes after budding. Figure adapted from Negroni and Buc, Nature Reviews 




1.7 Reverse Transcription in HIV-1 
One of the key steps in HIV replication involves copying the single-stranded plus 
sense RNA into double-stranded DNA (32). The conversion from ssRNA to dsDNA 
(reverse transcription) is catalyzed by HIV-RT in the following steps (Figure 1-6): 
1. The RNA to DNA conversion begins with the synthesis of the minus sense DNA 
strand. The minus strand DNA synthesis initiates with a tRNALys3 primer, 
packaged with the virus from the previous host cell. Instead of initiating DNA 
synthesis at the 3′ end of the RNA genome, the HIV-RT starts DNA synthesis 
close to the 5′ end at the primer binding site (PBS), located approximately 182 
nucleotides downstream of the 5′ end. The 3′ end of the tRNA binds to the PBS 
(Figure 1-6A).  
2. RT copies the genome up to the end of the 5′ repeat region (R, Figure 1-6B). The 
newly synthesized DNA is ~164 bp long and is known as the minus strand strong-
stop DNA (-sssDNA). The -sssDNA is translocated to the 3′ end of the genomic 
RNA (Figure 1-6C). Besides its polymerase activity, HIV-RT also has a 
ribonuclease H (RNase H) component. The RNase H activity degrades the 
template RNA while the synthesis of the minus strand DNA takes place (Figure 1-
6D). The minus strand DNA synthesis proceeds up to the PBS site, and the RNA 
template strand is almost completely degraded during this process. 
3. Only a 15 nucleotide (nt) portion in the RNA genome called the polypurine tract 
(PPT) is not degraded by RNase H during minus strand synthesis. The PPT is the 
site for initiation of plus strand DNA synthesis. (Figure 1-6E). The tRNA primer 






Figure 1-6: Schematic representation of HIV-1 replication. The HIV utilizes its 
reverse transcriptase (RT) to copy the single-stranded RNA into a double-stranded DNA 
(dsDNA). The minus strand DNA is initiated by a tRNALys primer, followed by transfer 
of the newly synthesized DNA strand to the 3′ end of the RNA genome. RT produces the 
minus strand, while RT degrades the RNA template save the PPT. Plus strand DNA 
synthesis starts at the PPT. After the second strand transfer, the plus and minus DNA 
strand use each other as templates to produce a fully synthesized dsDNA with long 
terminal repeat (LTR) ends. The LTRs facilitate integration of the dsDNA into the host 




synthesis starts at the 3′ end of the PPT. The plus sense strong stop DNA (+sss 
DNA) is produced when RT terminates at the 19th nucleotide from the 3′ end of 
the tRNA primer. 
4. After +sssDNA synthesis, the tRNA is removed from the 5′ end of the minus 
strand DNA by RNase H. This frees the 3′ end of the newly synthesized 
+sssDNA. Synthesis of the plus strand involves another strand jump by the 
+sssDNA to the 3′ end of the minus strand DNA, the PBS of the minus strand 
DNA and the 3′ end of the +sssDNA bind due to complementary base pairing 
(Figure 1-6F).  
5. The minus and plus strands utilize each other as templates for DNA synthesis 
until the double stranded DNA is fully made, creating long terminal repeat (LTR) 
ends (Figure 1-6H). The long terminal repeats (LTRs) are located at both the 5′ 
and 3′ ends of the double stranded DNA and are used during integration into the 
host genome (32).  
 
1.8 Reverse Transcriptase 
Reverse transcriptase was first discovered independently in the early 1970s by 
David Baltimore and Howard Temin (11, 167). HIV-RT is encoded from the pol gene. 
The functional enzyme is a heterodimer with two subunit components of 66 kDa and 51 
kDa. The RT enzyme is a DNA- and RNA-dependent DNA polymerase. HIV-RT also 
contains a Ribonuclease H (RNase H) domain, which degrades the RNA in the RNA-
DNA intermediate during reverse transcription (12). The 66 kD subunit (p66) provides 




kD subunit (p51) is derived from proteolytic cleavage of p66, 120 amino acids from the 
carboxy-terminus (C-terminus) (1). The RNase H domain lies in at the C-terminus of 
p66, while p51 only contains the DNA polymerase. Despite this, p51 shows little 
enzymatic activity, either on its own or in the dimerized form of RT (55, 105). The 
DNA polymerase activity and the RNase H activity in RT are found in p66. However, 
p66 attains optimal activity in the p66/p51 heterodimer, though p66 homodimiers also 
have activity. Even though the exact role of p51 in RT is unclear, p51 may provide a 
scaffold for protecting and stabilizing the p66 submit, interacting with the tRNA primer 
to initiate reverse transcription, and the binding of p66 to the primer-template (64, 164). 
 HIV-RT requires divalent cations as cofactors for both DNA polymerase and the 
RNase H enzyme activity (160). As with other polymerases, Mg2+ is the relevant 
physiological divalent cation although activity can be detected in vitro with others as 
well. The metal ions bind to the “catalytic triad” (Asp-110, Asp-185 and Asp-186) at the 
RT polymerase active site (73). Crystal structures of RT indicate that the enzyme 
assumes a right-hand conformation (80). Similar to other DNA polymerases, each subunit 
contains a finger, palm and thumb domain. The p66 palm and finger “grasps” the primer-
template closer to the active site of the DNA polymerase (98) (Figure 1-7). The RNase H 
active site has four conserved residues that also coordinate Mg2+ binding (Asp-443, Glu-
478, Asp-498 and Asp-549) (115, 139). The DNA polymerase and the RNase H active 
sites are about 18 bases apart, and primary RNA cleavage events occur ~18 bases 
downsteam of the 3′  end of the DNA primer in the RNA-DNA intermediate (80). 
Subsequent cleavage events that lead to shorter RNA cleavage products also occur after 






Figure 1-7: Structural representation of the catalytic subunit p66 in HIV-1 reverse 
transcriptase (RT) and its various domains with the RNA-DNA hybrid. The p51 
subunit is situated behind the palm domain of p66. The RNA template and the DNA 
primer are shown as the strands in blue and grey respectively. Figure adapted from 




HIV-RT does not possess 3′-5′ exonuclease activity to excise any misincorporated 
or mispaired nucleotides (16). Similar to the polymerases in many RNA virus, the lack of 
a proofreading activity in RT makes it a highly error-prone polymerase, especially when 
compared to the cellular DNA polymerase. RT has an error rate between 10-4 to 10-5 per 
incorporation event (1 error per 10,000 to 100,000 nucleotides incorporated) (17, 22, 
188). RT’s high error rate coupled with frequent recombination contributes to the genetic 
diversity of retroviruses, which has posed a problem in combating HIV/AIDS via drug 
treatment or vaccine developments due to escape mutants arising rapidly. 
 
1.9 Genetic recombination in HIV 
Due to the high error rate in the DNA polymerase during HIV replication, HIV 
undergoes frequent recombination of its genetic material. HIV packages two copies of its 
viral RNA genome in each virion. The two RNA strands can be genetically identical or 
vary greatly. The genetic diversity stems from the errors from the viral DNA polymerase 
during reverse transcription or the host RNA polymerase during RNA transcription. If the 
host cell is co-infected by HIV of two different subtypes (30), the progeny may contain 
genomic RNA from either or both of the subtypes. HIV recombination differs from 
recombination in prokaryotic and eukaryotic cells which involves strand breaking and 
rejoining. In retroviruses, most recombionation occurs during synthesis of the first DNA 
strand by a strand transfer/template switching mechanism referred to as “copy-choice” 
recombination. A second proposed mechanism for recombination occurs during second 
strand DNA synthesis and is termed “strand displacement-assimilation” (77). This 




recombination DNA being synthesized on one RNA genome (referred to as the “donor”) 
transfers (“switches”) to a homologous region on the second RNA genome (“acceptor”). 
DNA synthesis continues on the acceptor strand thus combining information from both 
strands. If recombination between two identical viral strands occurs, the progeny will 
remain the same as the parental strands (except for errors from the RT base 
incorporation). When the donor and acceptor are of a different genetic makeup, the 
recombined proviral DNA contains information from both the donor and acceptor. 
Progeny produced from the recombined provirus may be defective or may have a 
selective advantage under certain conditions or niches. It is by this mechanism that 
different viral subtypes as well as RFs and CRFs can originate (see section 1.2 for 
details). 
In addition to recombination occurring at internal regions of the viral genome, 
strand transfer is involved in two essential steps during HIV replication, as discussed in 
section 1.8. The first strand transfer occurs after the minus strand strong-stop DNA (-
sssDNA) “jumps” to the 3' end of the genome from the 5' end of the RNA template. The 
second strand transfer occurs when the plus sense strong stop DNA (+sssDNA) jumps to 
3' end of the minus strand DNA template, where the primer binding sites of the DNA 
template and the +sssDNA overlap. Both of the strand transfer events are terminal 
transfer, since DNA elongation is completed at the end of the template. 
Internal strand transfer events may occur at any position on the viral genome (85, 
195) and at any point during reverse transcription. The vast majority of internal strand 
transfer events occur between homologous regions of two genomic RNAs (74, 190). HIV 




3-10 recombinations per HIV replication cycle were found (195), and about 30 
recombinations per cycle in macrophages (107). Other simpler retroviruses have a much 
lower rate of recombination. For example, Moloney murine leukemia virus has 
recombination rates about 1/10 to 1/50 of the HIV (122), although more recent data has 
challenged these finding (196). Non-homologous recombination between RNA genomes 
has also been reported but occurs at a rate that is ~2-3 orders of magnitude lower (190). 
In addition to serving a role in generating genetic diversity, internal strand 
transfer events may increase the chances of completing replication if the one of the RNA 
genomes is damaged (31). The genetic diversity generated from the recombination also 
enhances the ability of HIV to evade other external factors, such as host immunity (75, 
94, 165).  
There are several restrictions on the HIV recombination during the replication 
process. After HIV infection, the viral protein U (Vpu) causes degradation of newly 
synthesized CD4 receptors in the host cell (185), while Nef removes the existing CD4 on 
the cell surface via endocytosis (4). This combined reduction of CD4 expression 
increases viral replication efficiency, however, it decrease the chances of another HIV 
virion entering the cell. Another restriction involves the dimer initiation sequences (DIS) 
of the different HIV subtypes. Although viruses from different subtypes (for example at 
type A and type C virus) can undergo recombination (159), the discrepancy between the 
DIS sequences in different HIV-1 subtypes can prevent the formation of heterodimers 
and thus limit co-packaging of the virion (46). This leads to a much lower rate of 
recombination between of viruses of different subtypes, especially when the DIS 




1.10 Antiretroviral Therapy 
Due to the highly variable nature and the long latency of the virus, an effective 
vaccine has not been developed. The five main classes of antiretroviral drugs approved 
by the Food and Drug Administration (FDA) (50) are: 
1. Nucleoside reverse transcriptase inhibitors (NRTIs), for example zidovudine 
(azidothymidine, or AZT), lamivudine (3TC), abacavir (ABC). AZT is the most 
commonly known and first anti-retroviral drug approved for HIV/AIDS treatment 
(52). NRTIs mimic their nucleoside counterparts and get incorporated into the 
elongating DNA strand during reverse transcription. The NRTIs act as chain 
terminators, as they lack the 3´-hydroxyl group, thus they cannot form the 
phosphoester bond with the next nucleoside and block further extension by HIV-
RT (57). 
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), for example 
nevirapine, etravirine, delvaridine. The NNRTIs works by binding non-
competitively at an allosteric “binding pocket” near the RT p66 subunit active site 
(78), thus preventing RT from transcribing the viral genome. 
3. Protease inhibitors, for example saquinavir, indinavir, ritonavir. Protease 
inhibitors are made of a short sequence of amino acids or amino acid analogs that 
bind to the HIV protease active site. Protease inhibition prevents proteolytic 
cleavage of long HIV polyproteins, causing the released virions to be non-
infectious (immature) due to the lack of functional viral proteins. 
4. Integrase inhibitors block the integrase-mediated strand transfer (the process by 




chromosomal DNA), therefore preventing the insertion of the viral DNA into the 
host DNA. The first and only FDA-approved integrase inhibitor is raltegravir 
(isentress, or MK-0518). Currently there are other integrase inhibitors in 
development. Examples include elvitegravir, a strand-transfer inhibtor to integrase 
currently in phase III clinical trial (154), and MK-2048, a second generation 
integrase inhibitor (6).  
5. Entry (or fusion) inhibitors, for example enfuvirtide (fuzeon) and maraviroc. 
Enfuvirtide is a peptide-based inhibitor that blocks the formation of the six-helix 
bundle in the transmembrane gp41 fusion glycoprotein (48). Enfuvirtide is only 
used for HIV patients when all other antiretroviral drug treatments have failed. 
Enfuvirtide is administrated with other antiretroviral drugs. Maraviroc blocks the 
interaction between the HIV surface protein (gp120) and the host cell chemokine 
receptor CCR5. However, maraviroc is ineffective against CXCR4-tropic HIV.  
 
The combination of three or four drugs from two or more of the above classes of 
therapeutics is known as Highly Active Anti-Retroviral Therapy (HAART). Patients 
under HAART still face the problem of HIV drug resistance. This is due to HIV having 
an error-prone DNA polymerase and high rates of genetic recombination. Thus, recent 
treatment protocols suggest starting HAART only when the CD4+ T cell counts are at or 
below (350 cells/µl). Alternative methods for combating HIV infection are currently in 
development. Viral release inhibitors, nucleic acid based inhibitors (aptamers) (87-89), 
small interfering RNA (siRNA) (151), and HIV Tat inhibitors (37) are just some of the 




1.11 Aptamers and Systematic Evolution of Ligands by Exponential Enrichment 
(SELEX) 
HIV-RT and several other proteins, even those that are not typical nucleic acid 
binding proteins, have been shown to bind strongly to particular RNA and DNA 
sequences, often based on the secondary and tertiary structures the sequences form (172, 
173). These tight binding sequences - aptamers - have several potential uses as antiviral 
agents, monoclonal antibody complements, in diagnostics, and in disease therapy (56, 82, 
88). Aptamers are mainly produced by a process called Systematic Evolution of Ligands 
by EXponential enrichment (SELEX). SELEX was invented in the early 1990s by the 
Gold, Joyce and Szostak labs independently (49, 90, 172) for selecting nucleic acid 
sequences that bind proteins with high affinity. SELEX selects from a library consisting 
of a large pool of nucleic acids (up to 1015 random sequences) incubated with a limiting 
amount of target. These specific targets are mostly proteins, but they also include nucleic 
acids, cultured cells, viruses and other small molecules (27, 67, 68, 103, 113, 133, 163, 
183, 184, 186, 191, 194). Nucleic acids that bind to the target (protein) with higher 
affinity will preferentially associate to form a complex. The nucleic acid-protein complex 
can be isolated by gel shift, nitrocellulose filter binding, column chromatography, or 
capillary electrophoresis (118). The nucleic acids that are bound to the target are 
amplified with reverse transcription Polymerase Chain Reaction (RT-PCR) for RNA 
aptamers, or PCR for DNA aptamers. New, enriched pools of nucleic acids are subjected 
to subsequent rounds of target binding. Approximately six to twelve cycles of the 
selection step are repeated until the sequences that show high affinity (usually with a 




The first aptamers isolated for HIV-RT were RNAs with pseudoknot-type 
structures (173). RNA pseudoknot aptamers have been shown to be potent RT inhibitors 
by interfering with RT primer-template extension (28, 65, 81). Later, SELEX was also 
used to select for single stranded DNA aptamers with similar properties of RT inhibition 
(118, 149). Tight binding to RT is mainly determined by the folded structure of the 
aptamer instead of aptamer sequence. These aptamers typically bind several-fold more 
tightly than the natural RT substrate (RNA-DNA or DNA-DNA primer-template) (65, 
96). Since aptamer binding depends on multiple contacts with RT amino acids, it is 
suggested that aptamers would produce fewer RT mutants that are resistant to the 
inhibitory effects of the aptamer, though more evidence is needed to support such a 
theory (65). Recent reports depict RT aptamer escape mutants (53, 89), however these 
escape mutants were replication defective in comparison to wild type virus. 
SELEX has enabled researchers to select for aptamers that bind to several HIV proteins 
and targets for other diseases (24, 56, 65, 99, 109, 111). Many of these aptamers are 
currently being developed as potential treatments for diseases. Other non-therapeutic uses 
for aptamers are also being explored including their uses as alternatives to antibodies in 
biochemical assays, diagnostic biosensors (known as aptamer beacons) (117), and as 
tools to study the mechanisms of viral replication (40, 82, 136). Essentially, any 
technique that involves a sensitive and stringent recognition of protein or nucleic acids 
could benefit from aptamer-based approaches. Currently the only Food and Drug  
Administration (FDA) approved aptamer-based drug is Macugen, which was developed  
by EyeTech Pharmaceuticals and is used to treat age-related macular degeneration 




few aptamer-based drugs is due to the limited success in human therapeutics (130). The 
main disadvantage of DNA aptamer therapy is the lack of an effective method for 
delivering the inhibitor to target cells in animal models, especially since host nucleases 
may degrade the inhibitor before it is able to bind to the target protein. Modified sugar 
and thiophosphate backbones can help protect against degradation, and the potential use 
of gene vectors for delivery of RNAs is being explored (24, 56). A new approach where 
oligonucleotides are anchored to small proteins to cargo the protein-nucleic acid complex 
across the cell membrane is also promising for both RNA and DNA aptamers and other 
types of nucleic acid inhibitors (171). Recent research suggests that aptamers can enter 
cells during viral infection without the transfection or conjugation to cargo proteins (110, 
111). Matzen et al. showed a DNA aptamer directed against the spleen focus-forming 
virus was able to inhibit viral infection not only in mouse cells, but also when 
administered to infected mice in vivo (110).  
Though currently limited as therapeutics due to cost and a lack of delivery 
systems, aptamers still hold a great deal of promise. Potential uses include not only 
targeting specific pathogen proteins, but also host proteins involved in pathogenesis. In 
such cases, aptamers should be useful in defining the potential efficacy of both pathogen 
and host targets. Finally, the possibility of therapeutic uses should not be overlooked, 







Figure 1-8: The SELEX process. For RNA- or modified RNA-aptamer discovery, the 
library is typically transcribed by using T7 RNA polymerase. The RNA molecules are 
allowed to fold and then incubated with the target protein (or nucleic acid) before the 
unbound species are partitioned from the bound RNAs. The latter are recovered, reverse-
transcribed and then amplified by PCR in order to produce a library of reduced 
complexity. This library is used to initiate a second cycle of SELEX. Binding of the 
enriched pool of RNAs to the target is monitored cycle by cycle and its RT-PCR products 
are cloned once it is judged that the proportion of binding sequences has risen to an 
adequate level, and they are analyzed individually. Figure adapted from James, J Gen 




Chapter 2: A primer-free method that selects high affinity single-
stranded DNA aptamers using Thermostable RNA Ligase 
2.1 Introduction 
Systematic evolution of ligands by exponential enrichment (SELEX) is a method 
for selecting small nucleic acid (RNA or DNA) molecules that bind with high affinity to 
specific targets. It was originally developed by three separate groups in the early 1990s 
(49, 90, 172). The selected nucleic acids are called “aptamers”. Though aptamer targets 
are most often proteins, they also include other small molecules, cultured cells, and 
viruses among others (27, 67, 68, 103, 113, 123, 133, 163, 183, 184, 186, 191, 194). 
Aptamers have many potential uses including therapeutic and diagnostic applications, as 
well as replacement of antibodies in ELISA and other technologies (24, 40, 56, 82, 88, 
117, 121, 136, 191). Essentially, any technique that involves highly specific recognition 
of protein molecules could benefit from aptamer-based approaches. Although several 
compounds developed from SELEX-based methods are currently in clinical trials, only a 
single drug for macular degeneration, Macugen (EyeTech Pharmaceuticals Inc. New 
York, NY USA), has been approved by the Food and Drug Administration (FDA).  
  Most aptamers are identified through standard SELEX procedures that include a 
starting pool of nucleic acids with a region of random nucleotides of approximately 20-50 
bases long. The random nucleotides are flanked on the 3′ and 5′ ends by fixed sequences 
of approximately 20 nucleotides. This results in oligonucleotides of ~60-90 nucleotides 
that are used for the selection process. After several rounds of selection tight binding 




modified to determine the minimal bases that are required for tight binding. A major 
advantage of this approach is that the flanking sequences provide a simple means to 
amplify oligonucleotides that are selected in each round of selection. A clear 
disadvantage is the potential for the fixed sequences to bias the selection by interacting 
with nucleotides in the random region of the oligonucleotide. Many, if not most selected 
aptamers require sequences from the fixed flanking regions to maintain tight binding.  
 Recently, new methods have been published for “primer-free” SELEX, in which 
selection occurs in the absence of any flanking, fixed nucleotides (126, 127, 184), and 
“minimal primer” SELEX, in which the fixed sequences are reduced to fewer nucleotides 
(83, 177), or other approaches in which primer ends are block or switched during the 
selection process (155). By eliminating fixed flanking regions (completely in the case of 
primer-free SELEX) during the selection step these methods abrogate the biases noted 
above. The trade-off is the methods are generally more times consuming than fixed 
sequence approaches, as several enzymatic and hybridization steps are involved to 
introduce flanking sequences after the selection step. These additional steps can introduce 
biases related to enzymatic reactions, and the additional steps can lead to loss of some 
material. The latter problem is especially important in the first round of selection where 
all or most sequences are unique.  
 In this report we introduce a new primer-free method for selecting DNA 
aptamers. The method takes advantage of a commercially available Thermostable RNA 
Ligase that functions at 60°C. Under the conditions as defined in this report, the ligase is 
capable of ligating DNAs with high efficiency (between ~50% and >90% depending on 




this application. Performance of ligations at high temperature also minimizes the 
potential effects of second structures on ligation. This method, although not solving all 
the problems inherent in primer-free SELEX, provides another tool for selection of high 
affinity aptamers using an approach that does not bias the outcome with fixed sequences.  
 
2.2 Materials and Methods 
2.2.1 Materials 
Human immunodeficiency virus reverse transcriptase (HIV-RT) was from 
Worthington Biochemical Corporation. Taq polymerase, restriction enzymes, Klenow 
DNA polymerase, T4 polynucleotide kinase (PNK) and T4 RNA Ligase 1 were from 
New England Biolabs. Thermostable RNA Ligase and CircLigase™ were from Epicentre 
Biotechnologies. Calf intestinal alkaline phosphatase (CIAP) and dNTPs were from 
Roche. Rapid DNA Ligation kits were from Promega. Nitrocellulose filters were from 
Whatman. PfuTurbo® DNA polymerase and StrataClone™ Blunt PCR cloning kits were 
from Agilent Technologies. Miniprep DNA preparation kits were from Qiagen. 
Radiolabeled compounds were obtained from Perkin Elmer. Sephadex G-25 spin 
columns were from Harvard Apparatus. All oliognucleotides were from Integrated DNA 
Technologies. The 30 nucleotide random sequence oligomer (5′-N30-3′) used as a starting 
pool for selection was synthesized using “hand-mixed” ratios of the four nucleotides in 
order to assure an equal probability of incorporation of each nucleotide at each position. 
This material was used directly in the SELEX protocol. All other chemicals were from 





5′ end-labeling of oligonucleotides: Reactions for labeling of the starting material 
(5′-N30-3′) were done in a 100 µl volume containing 1500 pm of 5′-N30-3′, 70 mM Tris-
HCl, pH 7.6, 10 mM MgCl2, 5 mM dithiothreitol (DTT), 10 µls of γ-
32P ATP (3000 
Ci/mmol, 10 µCi/µl) and 2 µls (20 units) of T4 polynucleotide kinase. Because of the 
large excess of oligonucleotide over label, only a small fraction of the primers have 
phosphate added to the 5′ end. This limits circularization of this oligonucleotide and 
favors ligation to oligonucleotide 1 (see below) in the ligation reaction with Thermostable 
RNA Ligase. The reaction mixture was incubated for 30 minutes at 37oC and then the 
PNK was heat inactivated for 10 minutes at 70oC according to manufacturer’s 
recommendation. The material was then run through a Sephadex G-25 spin column.   
Labeling of oligo 1 (5′-/5′Phos/GTCGACGAGGTCTAGAATA/3′dideoxyC/- 3′, 
MnlI site underlined) was performed as above, except that 200 pmoles of oligo 1 (without 
a phosphate at the 5′ end) were incubated in a 50 µl volume as above for 15 minutes. 
After this non-radioactive ATP was added to a final concentration of 200 µM and the 
reaction was continued for 20 minutes then processed as described above.   
 
 Selection of material with HIV-RT using nitrocellulose filters for rounds 1 and 2 
and subsequent processing: In the initial round, 3 separate reactions with approximately 
500 pm each of a 5′ 32P end labeled 30 nucleotide oligonucleotide of random sequence 
(5′-N30-3′) and 10 pm of HIV-RT were prepared in 50 µl of buffer containing 50 mM 
Tris-HCl (pH=8), 80 mM KCl, 6 mM MgCl2, and 1 mM DTT. The reactions were 




mm, 0.2 µm pore size) with suction. Disks were preincubated in the above buffer prior to 
use, then washed twice with 500 µl of buffer containing 25 mM Tris-HCl (pH=8) and 10 
mM KCl. Filter disks were then cut into small pieces and placed in 500 µl of 50 mM 
Tris-HCl (pH=7) and 1 mM EDTA (pH=8). The material was then incubated at 90ºC for 
5 minutes then 70ºC for 10 minutes. After allowing the material to cool, it was extracted 
with 500 µl of 25:24:1 phenol: chloroform: isoamyl alcohol, followed by 500 µl of 
chloroform. The aqueous phase was precipitated by adding 50 µl of 3 M sodium acetate 
(pH=7), 40 µg glycogen, and 1 ml of ethanol. Precipitated material was collected by 
centrifugation after incubation at -20ºC for several hours. The pellet was washed with 
70% ethanol, then dried in a DNA SpeedVac Concentrator. The precipitated material was 
resuspended in 75 µl of water and passed over Sephedex G-25 spin columns equilibrated 
in water. Collected material was then dried. Nucleic acid from all 3 reactions (~20 pm 
total) was then combined and re-selected as above but in a 20 µl final volume using 2 pm 
of HIV-RT. This step was necessary to reduce the total amount of nucleic acid for the 
ligation reactions. Nucleic acid (~0.3 pm total) was extracted as described above, except 
glycogen was omitted from the precipitation step and 30 pm of 5′ 32P end labeled oligo 1 
(see above) was added. The collected precipitate was once again run over a Sephadex G-
25 spin column as described above and dried. The dried material was resuspended in 21 
µl of water and ligations were performed in 3 separate ligation reactions using 
Thermostable RNA Ligase. All reactions were in 20 µl final volume containing: 50 units 
(0.5 µls) Thermostable RNA Ligase, ~10 pm 5´ 32P end labeled oligo 1, ~0.1 pm 5′-N30-
3′, 50 mM MOPS (pH=7.5), 5 mM MgCl2, 10 mM KCl, 1 mM DTT, 50 µM ATP, 1 mM 




incubated 12-18 hours at 60ºC in a thermocycler with a heated lid. After ligation 
reactions, 20 µl of 2X loading buffer (90% formamide, 20 mM EDTA (pH=8), 0.025% 
(w:v) each of bromophenol blue and xylene cyanol) was added and samples were run on 
a 12% polyacrylamide/7M urea denaturing gel (in 1X Tris/borate/EDTA buffer) with a 
molecular weight marker as described (145). Ligated material (50 nucleotides in length) 
was located using a phosphoimager (Fujifilm FLA-7000), excised, and then eluted by the 
crush-and-soak method (145) in 500 µl 50 mM Tris-HCl (pH=7), 1 mM EDTA (pH= 8). 
Forty µg of glycogen was added to the eluate and the nucleic acid was recovered by 
ethanol precipitation as described above. The 5′ ends of the recovered nucleic acid were 
phosphorylated in a standard PNK reactions as described above, except the total volume 
was 25 µl, 20 mM KCl was included, radiolabeled ATP was replaced with 0.4 mM cold 
ATP and 10 units of PNK were used. After inactivating the PNK (see above), 10 µg of 
oligo 2 (5′-CTGGTATTCTAGACCTCGTC-3′, MnlI site underlined) was added. This 
oligo was complementary to a region on oligo 1 (see Fig. 1). Oligo 2 was hybridized to 
the ligated product by heating to 65ºC, and slow cooling to room temperature. Then an 
extension reaction was performed with Klenow DNA polymerase (1 unit total) by adding 
dNTPs (final concentration 100 µM) and bringing the volume up to 50 µl, followed by 
incubation at 37ºC for 10 minutes. The reaction volume was then increased to 100 µl with 
water and the material was extracted and precipitated. The recovered double stranded 
DNA was blunt-end ligated to a duplex formed using oligo 3 (5′-
ATAGCATGAATTCCCGAAGACGC-3′, BbsI site underlined) and oligo 4 (5'-
CGTCTTCGGGAATTCATGC-3′, BbsI site underlined) using a rapid DNA ligation kit 




reactions, and 1 pmole was used in subsequent rounds. The manufacture’s recommended 
protocol was used in the rapid ligation reactions which were incubated for 30 minutes at 
room temperature. The entire 10 µl ligation reaction (round 1) or 5 µl of the reaction (all 
subsequent rounds) was used in a polymerase chain reaction (PCR). Reactions were 
performed in the manufacturer’s supplied buffer in 100 µl total volume, and included 
fifty pmoles each of oligo 2 and oligo 5 (5′-GCATGAATTCCCGAAGACGC-3′), 200 
µM each of dATP, dCTP, and dGTP, 25 µM dTTP, 2 µls of α-32P dTTP (800 Ci/mmol, 
10 µCi/µl), and 2.5 units of Taq polymerase. A total of 15-18 cycles was performed using 
94ºC (30 seconds), 50ºC (1 min), and 72ºC (1 min) followed by an additional cycle of 5 
min at 72oC. Native gel loading buffer (20 µl: 40% sucrose, 0.25% (w/v) bromophenol 
blue, 0.25% (w/v) xylene cyanol) was added and reactions were run on a 12% native 
polyacrylamide (29:1 acrylamide:bisacrylamide) gel and products of the correct size (73 
base pairs) were located and recovered as described above using a phosphoimager. 
Approximately 1/40th (for each reaction) of the recovered material was used in a second 
set of 4 PCRs. The PCRs were performed as described above for 6, 8, 10, or 12 cycles. A 
range of cycles was performed to insure that a sufficient quantity of the correct product 
was recovered. If product recovery was too low, another PCR was performed using an 
optimal cycle number based on the results with the variable cycle reactions. Because of 
the random 30 base region of the product, too many cycles results in the generation of 
multiple single strands that do not form complete duplexes. Products of the correct size 
from the 4 PCRs were recovered from 12% native gels as described above. The eluted 
material was precipitated and digested in 30 µl total volume with 7.5 units each of BbsI 




heated to 90ºC for 3 min, then cooled rapidly on ice. Four units of CIAP were added and 
incubation was continued at 37ºC for an additional 30 min. Twenty-five µl of 2X loading 
buffer was added and the sample was run on a 12% denaturing gel as described above. A 
marker for the 30 nucleotide single stranded dephosphorylated product was included on 
the gel. The correct product was located with a phosphoimager and recovered using 40 
µg of glycogen to aid precipitation as described above. The recovered material (~10-20 
pmoles) was used for a second round of selection with nitrocellulose filters using the 
same protocol with the changes noted.   
 
Selection procedure for all rounds after round 2 performed by gel-shift: 
Following the second round, subsequent rounds were conducted using native 6% 
polyacrylamide gels to recover the selected material by gel-shift. The recovered 30 
nucleotide product from the previous round was incubated with HIV-RT (see below) in 
10 µl final volume using the conditions stated above for 30 minutes. Two µl of native gel 
loading buffer was then added and the material was run on a 6% native polyacrylamide 
gel at ~100 V until the blue dye marker was ~2-3 inches below the wells. Gel-shifted 
nucleic acid was located with a phosphoimager and eluted as described above. Ten 
pmoles of radiolabeled oligo 1 was added to the eluate and precipitation in the absence of 
glycogen was carried out as described above. The recovered material was processed as 
described above to regenerate the 30 nucleotide random nucleic acid for the next round of 
selection. After round 6, the KCl concentration in the selection step was increased from 
80 to 150 mM. Various amounts of HIV-RT were used in the selection process. Our goal 




shifted material on the gels. In round 3, the first round where the gel-shift was used, 5 
pmoles of HIV-RT was added to the selection reaction. In subsequent rounds the level 
was decreased as the amount of recovered material from the previous round increased. By 
round 6, 0.5 pmoles of HIV-RT was being used and this amount was used in all 
subsequent rounds. 
 
Sequences analysis of products recovered from selection rounds 6, 11, and 12: 
The sequence of the 30 nucleotide random region from products selected in rounds 6, 11, 
and 12 was determined by performing a PCR with PfuTurbo® DNA polymerase, and 
then cloning the 73 base pair PCR product using StrataClone™ Blunt PCR cloning kit 
from Agilent Technologies and the manufacturer’s suggested protocol. Mini-preps were 
prepared by the QIAprep Miniprep Kit from Qiagen. Products were sequenced by 
Genewiz Inc. 
 
Determination of equilibrium dissociation constants (Kd): Selected material (~2 
nM) from various rounds of selection (see Results) or other designed sequences (see Fig. 
5) were either labeled internally, or 5′ end labeled with 32P and mixed with various 
amounts of HIV-RT (as stated in Fig. legends) in 10 µl of buffer containing 50 mM Tris-
HCl (pH=8), 1 mM DTT, 80 mM KCl, and 6 mM MgCl2, for 10 min at room 
temperature. Two µl of 6X native loading buffer was added and the samples were run on 
a 6% native polyacrylamide gel as described above for the gel-shift experiments. The 
amount of shifted vs. non-shifted material was quantified using a phosphoimager. Values 




concentration of HIV-RT and fitting the data by nonlinear least square fit to the quadratic 
equation: [ED] = 0.5([E]t + [D]t + Kd) – 0.5(([E]t + [D]t + Kd)
2 – 4[E]t[D]t)
1/2, where [E]t 
is the total enzyme concentration and [D]t is the total primer-template concentration (72). 
In cases where the affinity of HIV-RT for the nucleic acid was low (Kd ≥ 1 µM), a more 
precise Kd value was not determined.   
 
2.3 Results and Discussion 
2.3.1 The efficiency of the selection process and its effect on the recovery of tight binding 
aptamers 
In the initial selection round with an oligonucleotide of 30 bases (5′-N30-3′, see 
Figure 2-1), nearly all nucleic acid sequences are unique. With 500 pmoles (5 x 10-10 
moles) of starting material, only ~0.026% of the total number of possible sequences is 
represented ([((5 x 10-10) x (6.023 x 1023))/430] x 100). On the surface this would suggest 
that many, if not most sequences that may bind very tightly to a protein, are unlikely to 
be present. However, proteins often recognize shorter nucleotide runs or specific 
structures that can form from a diverse array of sequences. Even if a particular protein 
bound tightly to a run of 20 specific nucleotides, such a run would be represented ~270 
times in the 500 pmoles pool (((5 x 10-10) x (6.023 x 1023))/420). Because of the way 
proteins recognize nucleic acids, it is highly likely that most of the possible recognition 
are motifs or sequences that could form with a nucleic acid that is 30 nucleotides or 
shorter would be present in a 500 pmole starting pool. More complex structures, for 
example duplexes resembling primer-templates with recessed 3′ termini, or nucleic acids 






Figure 2-1: Protocol for primer-free SELEX. A schematic diagram of the protocol for 
selecting 30 nucleotide aptamers is illustrated. Various intermediates are shown (Products 
A-E) and labeled for reference in the text. Primers used in the protocols are shown at the 




to occur in the starting material, mostly because of the short 30 nucleotide length.   
Assuming that the starting pool has reasonable but not complete diversity, it is 
important that those oligos in the pool that can bind with high affinity to the protein 
(HIV-RT in this case) are recovered. Since nearly all the sequences in the pool are 
unique, any sequence not recovered from round 1 is essentially lost. This is not a major 
issue in subsequent rounds since PCR amplification after round 1 generates many copies 
of each recovered sequence.   
In the protocol used here the first and second rounds of selection were performed 
using nitrocellulose filters, while subsequent rounds were performed using gel-shift 
(Figure 2-1). Filter selection was faster, allowing rapid processing of larger amounts of 
material and high recovery. For these reasons it was advantageous to use this approach, at 
least for rounds 1 and 2. Later rounds used gel-shift because of preference to this 
approach due to lower background and higher selectivity. However, many proteins are 
unable to shift nucleic acids on gels. In such cases it is feasible to continue with filter 
selection, and we are currently doing this for some other proteins being tested in this 
protocol (data not shown).   
Even with the high recovery efficiency of the nitrocellulose approach, it is 
impossible to achieve 100% recovery of tight binding sequences. To minimize the 
potential loss of high affinity sequences, for round 1 three separate selections with 500 
pmoles each were conducted then combined. The combined material was reselected in 
order to decrease the total amount of material for the first ligation step. This was 
necessary to achieve the highest efficiency in the ligation reaction which required a high 




amount of recovered material was still relatively high after the two sequential selections, 
three separate ligations with Thermostable RNA Ligase were performed (see steps 
between products A and B in Figure 2-1). An experiment was performed to test the 
efficiency of the ligation process. A drawback of using T4 RNA Ligase 1 in a DNA 
selection is its relatively low efficiency at ligating DNA. The efficiency can be improved 
using hexaminecobalt chloride and polyethylene glycol (168). Even using these optimal 
conditions, T4 RNA Ligase 1 only ligated ~30% (see Figure 2-2 legend) of the 5′-N30-3′ 
DNA to oligo 1 to produce the specific 50 nucleotide ligation product as shown in the 
experiment in Figure 2-2A. Thermostable RNA Ligase was more efficient ligating about 
50% of the material. Thermostable RNA Ligase also produced less nonspecific ligation 
products than T4 RNA Ligase 1. A second thermostable ligase, CircLigase™, was about 
as efficient as T4 RNA Ligase 1, though as expected it did circularize the 5′-N30-3′ DNA 
with higher efficiency (data not shown). We should note that in order to make detection 
and quantification of ligated products easier, the ligation tests shown in Figure 2-2A (and 
Figure 2-5 below) were conducted using 5′ end-labeled (and thus 5′ phosphorylated) 5′-
N30-3′ and unlabeled oligo 1, while in the ligation reactions used for selection the 5′ end 
of 5′-N30-3′ was not phosphorylated. Phosphorylating the 5′ end of the acceptor increases 
the likelihood of circularization, which would decrease the level of acceptor available for 
ligation to oligo 1. This could in turn lead to an underrepresentation of the actual level of 
ligated product in the selection reactions. Although some circularization did occur (see 
Figure 2-2A), ligation to oligo 1 was more pronounced, probably because of the 100-fold 
excess of the oligo 1 donor to the 5′-N30-3′ acceptor. Also, this approach did not seem to 





Figure 2-2: Ligation reactions with T4 RNA Ligase 1 and Thermostable RNA 
Ligase. (A) In these reactions a small fraction of the 5′-N30-3′ starting material was 
labeled with 32P at the 5′ end (see Methods) in order to follow the ligation process. The 
starting material was ligated to oligo 1 (with cold phosphate at the 5′ end) in Figure 1 
(oligo 1:starting material, 10 pm:0.1 pm) using either T4 RNA Ligase 1 (10 units) or 
Thermostable RNA Ligase (0.5 units) for ~ 8 hours as described under Materials and 
Methods. Reactions were run on 12 % denaturing polyacrylamide gels and dried gels 
were visualized using a phosphoimager. These reactions differ slightly from standard 
SELEX reactions where oligo 1 was radioactively labeled at the 5′ end while the 5-N30-3′ 
nucleic acid was dephosphorylated in all rounds except round 1, where a small fraction 




correctly ligated product (Product B in Figure 2-1) are indicated along with locations or 
aberrant ligations products which may include circularized products or products with 
more than one oligo 1 or 5′-N30-3′. The location of circularized 5′-N30-3′ monomers, 
which occur due to the 5′ 32P labeling (see text), is also indicated. A DNA molecular size 
marker indicating positions (in nucleotides) of specific size standard is also shown (lane 
M). Ligation efficiency for the formation of the 50 nucleotide product was 31 ± 8 % (ave. 
of 2 exp. ± standard deviation) and 51 ± 7 % (ave. of 4 exp.) for T4 RNA Ligase 1 and 
Thermostable RNA Ligase, respectively. (B) Ligation experiment performed with 
unlabeled 5′ dephosphorylated 5′-N30-3′ and unlabeled 5′ phosphorylated oligo 1, after 
the reaction products were radioactively labeled with T4 PNK using an exchange-




conducting a ligation reaction with non-phosphorylated 5′-N30-3′ and oligo 1, then end-
labeling the resulting products in an exchange-reaction with PNK (Figure 2-2B). The 
proportion of correctly ligated (50 nucleotide product) vs. non-ligated material was 
similar (~50% efficiency) in this experiment in comparison to those with 5′ end-labeled 
5′-N30-3′. Although circularization did not significantly interfere with quantification of 
ligation using 5′-N30-3′, it may interfere with oligos of a specific sequence or with longer 
oligos that could circularize more easily. Recently published primer-free or minimal 
primer (2 fixed nucleotides at the 3′ and 5 ends flanking a random region) approaches 
that used a more complex ligation step with a “bridging” nucleic acid and T4 DNA ligase 
report >90% efficiency for the ligation step of the minimal primer approach, while the 
efficiency in the primer-free approach was not specified (127). A second method termed 
“primer-free genomic SELEX” reported somewhat lower efficiencies (184). Given the 
complexities of these various methods and the one used in this manuscript, it is difficult 
to compare their overall efficiency by comparing results from a single step or even 
multiple steps in the protocols. It would be interesting to compare the results of these 
approaches to see if they select similar aptamers.   
Although the efficiency of the ligation step results in a significant loss of diversity 
in round 1, some of this loss is made up by conducting multiple selections and ligations 
in the first round. As noted above, this issue is less important in subsequent rounds. There 
is also the possible loss of diversity due to the Thermostable RNA Ligase having a bias 
for ligating specific sequences or nucleic acids with less structure. T4 RNA ligase has 
been shown to ligate specific DNA sequences preferentially (63). Although this is also 




suggests that the bias may be less pronounced. Inhibition of ligation because of high 
structure is also likely to be less pronounced because the reactions are performed at 60ºC.   
Following recovery of the ligated 50 nucleotide product (Figure 2-1, product B), a 
set of reactions was performed to produce a blunt-ended 53 base pair duplex, with a 5′ 
phosphate at the end containing the random region (Figure 2-1, product C). The 3′ end of 
the upper strand in product C is derived from Oligo 1, however, the 3′ dideoxycytidine 
residue is replaced by a deoxycytidine and is followed by a 5′-CAG-3′ sequence. This 
depiction was based on the assumption that the 3′-5′ exonuclease activity of the Klenow 
polymerase would excise the dideoxy residue and add four template-directed nucleotides.  
Oligo 2, which was used to prime the step with Klenow, was not complementary to the 
first three 5′ nucleotides of oligo 1. This is due to a previous version of this oligo with 
complete complementarity produced primer dimers in the subsequent PCRs. The 5′ 
phosphate at the random end of product C was added by PNK before the Klenow step. It 
directed ligation by T4 DNA ligase of the oligo 3-oligo 4 duplex to this end. The oligo 3-
oligo 4 duplex was staggered in order to force blunt end ligation in the correct orientation 
(Figure 2-1, product D). The blunt-end ligation step using the rapid ligation kit and a vast 
excess of the oligo 3-oligo 4 duplex typically showed a ligation efficiency of >60% (data 
not shown). 
After producing product D, an initial PCR step was performed for 15-18 cycles 
(see Methods). Material from this step was isolated on a native gel. About 1/40th of the 
total recovered material was used in a second PCR step that was performed in 4 separate 
reactions using a range of cycles (see Methods). Amplification steps must always be 




cannot form a complete duplex, due to the random region while too few cycles produce a 
low yield. This is easily followed on a native gel, where the desired product appears and 
builds up over a range of cycles then is lost as too many cycles are performed. Although 
the approach used here was effective, in many cases a single PCR step with multiple 
reactions conducted for 15-18 cycles (depending on the level of the starting material) 
would produce sufficient yield for the next round.  
Cleavage of the PCR products to reproduce the 5′-N30-3′ product (Figure 2-1, 
product E) was highly efficient (Figure 2-3). Note the system can be designed to select 
single stranded products in a wide range of sizes, provided that cleavage of the PCR 
product yields a product of unique size for the selected material. This may require using 
primers in the PCR step, or linkers that are different sizes than the ones employed here. 
 
2.3.2 The analysis of the SELEX procedure by monitoring binding to HIV-RT, and the 
nature of the recovered aptamers 
The 30 nt material (Figure 2-1, product E) from select rounds was analyzed in a 
gel-shift assay to estimate binding affinity for HIV-RT (Figure 3-4). Results were 
compared to the starting material and Kd values were estimated. Note that this approach 
does not yield a true Kd value, as gel-shift is not an equilibrium binding method. 
However, the derived values are useful in comparing the binding affinity of material from 
the various rounds. The starting material bound weakly to HIV-RT with Kd value of ~1 
µM. Attempts to measure the value more precisely were not performed as large amounts 
of enzyme would be required, and this resulted in a smearing effect in the gel-shift. The 





Figure 2-3: Cleavage of PCR product with BbsI and MnlI to regenerate 30 
nucleotide selected material. A cleavage reaction run on a 12% denaturing 
polyacrylamide gel is shown for cleavage of the 73 nucleotide double stranded PCR 
product (equivalent to Product D in Fig. 1 minus the 5′ overhang) with BbsI and MnlI. 
Correct cleavage would produce 23, 24, 25 and 30 nucleotide products on a denaturing 
gel with the last being the selected material. Some undigested and partially digested 






Figure 2-4: Gel-shift analysis of starting material and material from rounds 6, 10, 
and 11 of primer-free SELEX. An example of a gel-shift experiment run on a native 6% 
polyacrylamide gel is shown. Increasing amounts of HIV-RT (as indicated above wells, 
note higher amounts used for starting material) were mixed with 30 nucleotide 5′-N30-3′ 
derived from the starting material or rounds 6, 10, and 11 as described under Methods. 
Starting material was 5′ end-labeled with 32P, while rounds 6, 10, and 11 were internally 
labeled during the SELEX procedure (see Methods). Positions of shifted and unshifted 





170 ± 56 nM, 191 ± 42 nM, and 142 ± 31 nM (rounds 6, 10, and 11 are an average of 3 
exp. ± standard deviation), respectively. Interestingly, the affinity did not increase 
appreciably after round 6, despite five more rounds of selection at higher salt 
concentrations (see Methods). A second independent SELEX procedure was also 
performed. The Kd value after 9 rounds was similar to the value for the round 11 material 
in the first SELEX and the sequences recovered were nearly identical (see below).    
 
2.3.3 Aptamer sequences recovered from round 11 of the first SELEX and round 9 of the 
second were nearly identical and had little secondary structure 
Ten clones were sequences from the round 11 material. Only two different 
sequences (denoted R11-1, or PF1 in subsequent chapters and R11-2 in Table 2-1) were 
recovered and both were closely related, differing only by the first nucleotide. These 
same sequences were also the predominant oligos found in material sequenced from 
round 6, which explains the similar affinity of material from these rounds for HIV-RT. 
Gel-shift assays with each sequence revealed that they had similar affinity for HIV-RT. 
Interestingly, using the DNA mfold program (197), both sequences had a very low level 
of predicted secondary structure with the most stable predicted structures having ∆G 
values of -0.61 kcal/mole for both sequences. A possible explanation for this is that 
Thermostable RNA Ligase preferentially ligates material with low structure (see below). 
This would seem to make sense as availability of the 3′ end of the nucleic acid would be 
pivotal in the ligation step. However, this factor should be mitigated to some extent by 
the 60ºC reaction temperature. Also notable was the regular arrangement of 4 separate G 




structure. Several sequences closely related to R11-1 (PF1) and R11-2 were also 
recovered from round 9 of the second SELEX experiment (Table 2-1). Experiments were 
conducted to determine why the selected aptamers bind tightly to HIV-RT (Chapter 3).   
 
2.3.4 The ligation efficiency of Thermostable RNA Ligase improves with low structure 
and a T residue at the 3′ terminus of the acceptor 
The significant increase in binding affinity of the round 11 selected material to 
HIV-RT indicated that the RT binding step likely played a major role in the selection 
process for this protocol. However, this does not rule out the possibility that 
Thermostable RNA Ligase may have also influenced selection. To test this further, the 
ligation efficiencies of the starting material and material selected from rounds 2, 6 and 11 
were tested (data not shown). Starting material (see above) and material from round 2 
each showed ~ 50% ligation efficiency in standard 8 hour ligation reactions, while 
efficiency was greater than 90% for round 6 and 11 materials.   
The more efficient ligation of the selected material suggests that Thermostable 
RNA Ligase may have played some role in the selection process. However, it is also 
possible that material that binds tightly to HIV-RT just happens to ligate efficiently 
because of other properties. For example, low structure may favor binding to RT by 
allowing the aptamer to be flexible, while it also promotes higher ligation efficiency. 
Also, it was notable that all the aptamers recovered from round 11 (and round 6 (data not 
shown)) terminated with a T residue at the 3 end. Several oligonucleotides were designed 
to try and determine why the selected material ligated more efficiently. These included 








 # of times 
recovered 
in round 






5′-N30-3′ NA ~1000 
SELEX Experiment 1 
R11-1 
(PF1) 
5′-AGGAAGGCTTTAGGTCTGAGATCTCGGAAT-3′ 9/10 82 ± 7  
R11-2 5′-GGGAAGGCTTTAGGTCTGAGATCTCGGAAT-3′ 1/10 102 ± 15 
SELEX Experiment 2 
E2R10-1 5′-AGGAAGGCTTTAGGTCTGAGATTTCGGGAT-3′ 1/10 ND 
E2R10-2 5′-AGGAAGGCTTTAGGTCTGAGATTTCGGTAT-3′ 2/10 ND 
E2R10-3 5′-AGGAAGGCTTTAGGTCTGAGATCTCGGAAT-3′ 3/10 ND 
E2R10-4 5′-AGGAAGGCTTCAGGTCTGAGATTTCGGAAT-3′ 1/10 ND 
E2R10-5 5′-AGGAAGGCTTTAGGTCTGAGATTTCGGTGT-3′ 1/10 ND 
E2R10-6 5′-AGGAAGGCTTTAGGTCTGAGATCTCGGTAT-3′ 1/10 ND 
E2R10-7 5′-AGGAAGGCTTTAGGTCTGAGATTTCGGTAT-3′ 1/10 ND 
1
For experiment 1 names indicate the round of selection from which the sequence was 
recovered followed by a designated number. For experiment 2, the name is preceded by an 
“E2” designation. 
2
Underlined nucleotides in the recovered sequences indicate differences from the R11-1 
sequence recovered in the first SELEX experiment.  
3
Equilibrium dissociation constants (Kd) were determined using a gel shift assay as described 
under Material and Methods. Results for R11-1 (PF1) and R11-2 are an average of 3 
experiments ± standard deviation. The result for “Starting material” was an estimate based on 
repeated experiments.  
ND- Not determined; NA-Not applicable.  
 





contain little or no secondary structure (Figure 2-5A). A set of 30-mer oligos had 
sequences related to the round 11 selected material but with the 3′ terminus either 
protruding or bound in a stem structure (3′-overhang and 3′-recessed, respectively); and 
finally, a highly structured sequence 30 nt G-C rich sequence (G-C flip-back). Ligation 
reactions for these oligos and the R11-1 (PF1) aptamer and 5′-N30-3′ starting material 
were performed for 30 min, 2 hr and 8 hr and plotted as shown in Figure 2-5B. Both R11-
1 (PF1) and 5′-T30-3′ ligated with very high efficiency, reaching ~70% ligated product by 
30 min and over 90% by 2 hours. The ligation advantage was not due solely to a lack of 
structure, as 5′-dA30-3′ ligated with much lower efficiency that was comparable to 5′-N30-
3′. Interestingly, the 3′-overhang and 3′-recessed oligos ligated better than starting 
material or 5′-dA30-3′ and were comparable, despite the latter essentially “protecting” the 
3′ end in a secondary structure. Finally, the highly structured G-C flip-back ligated very 
poorly, although this may have been at least partially due to the 3′ G residue (see below). 
  To test the effect of a T residue at the 3′ end of the acceptor oligo, three 
derivatives of R11-1 (PF1) in which the 3′ terminal nucleotide was replaced with A, G, or 
C were also tested in ligation reactions along with R11-1 (PF1) and a version of the 
random starting material with a T at the 3′ end (5′-N29T-3′) (Figure 2-5C). While oligos 
terminating in T, A, or C all showed greater than 90% ligation efficiency in 8 hour 
reactions, the T terminated oligo ligated far more efficiently at early time points followed 
by A then C in ligation efficiency. The version of R11-1 (PF1) with a 3′ G residue ligated 
much more poorly than the others. The importance of a T residue at the 3′ end is 
emphasized most strongly by ligation experiments with 5′-N29T-3′ (Figure 2-5C, filled 




single 3′ T residue. Ligation with 5′-N29T-3′ essentially mimicked that with R11-1(A) and 
reached a level of ~90% after 8 hours while 5′-N30-3′ was only between 50-60% (Figure 
2-5B, filled circles) at this time point. This finding suggests that it may be advantageous 
to start the selection process with random oligos that include a fixed T residue at the 3′ 
end. This would decrease the loss of diversity in the early rounds of the protocol, though 
it would also create some bias in the results.       
  The above results indicate that Thermostable RNA Ligase showed a clear 
preference for a T residue at the 3′ end of the acceptor, at least for ligation to the oligo 1 
donor that was used here. Low structure was also advantageous, as modestly structured 
oligos closely related to R11-1 (3′-recessed and 3′-overhang) ligated with lower 
efficiency. Although strong binding to HIV-RT clearly played an important role in the 
selection process, it is not clear if, and to what extent Thermostable RNA Ligase 
sequence/structural preferences influenced the process. Selections using this method with 
other proteins are ongoing and should help in answering this question. The fact that only 
sequences with a 3′ terminal T were recovered suggests that the ligase played at least 
some role, as deletion or replacement of the T does not affect binding to RT (data not 
shown). If this method preferentially selects low structure aptamers then it may be 
particularly useful for finding aptamers that could potentially be used as inhibitors in 
cells, as highly structured nucleic acids have a tendency to activate innate cellular 






Figure 2-5: Ligation of various 30 nucleotide oligos to oligo 1 with Thermostable 
RNA Ligase. Ligations were carried out for 0.5, 2, or 8 hours using conditions described 
in Figure 2-2A. Products were visualized as described in Figure 2-2 and quantified using 
a phosphoimager. (A) Predicted structures (using DNA mfold (197)) of the 30 nt oligos 
ligated to oligo 1 (see Figure 2-1), panel B. Only those oligos with a predicted secondary 
structure are shown. The predicted ∆G value in kcal/mol using the conditions of 80 mM 
NaCl, 6 mM MgCl2 and 37°C is also listed for each structure. (B) Plot of the percent of 
30 nt oligo ligated to oligo 1 vs. time. (C) Ligation plots for R11-1 (terminal 3′ T) or 
R11-1 in which the 3′ terminal T was changed to A, C, or G, and 5′-N29T-3′. All 





2.4 Conclusions and significance 
 Just a few protocols for primer-free SELEX are currently described in the 
literature (see Introduction). Primer-free SELEX is advantageous because it allows 
selection of nucleic acid aptamers from random pools without interference from fixed 
flanking regions. Though all these methods are considerably more complex than SELEX 
approaches using flanking fixed sequences, the method proposed in this report takes 
advantage of a new Thermostable RNA ligase. In comparison to other primer-free 
methods, this simplifies the procedure for regenerating nucleic acids for subsequent 
rounds of selection. In practice each primer-free method may have specific advantages or 
biases and it would be interesting to compare the aptamers selected from the various 





Chapter 3: Comparative study of HIV-RT aptamers from a primer-
free SELEX approach with various classes of RT aptamers 
3.1 Introduction 
Since its invention by three separate groups in the early 1990s (49, 90, 172), 
Systematic evolution of ligands by exponential enrichment (SELEX) has been used for 
selecting small nucleic acids (RNA or DNA) which bind to specific targets with high 
affinity. SELEX starts with a large random pool of nucleic acid incubated with a limiting 
amount of target. These specific targets are mostly proteins, but they also include nucleic 
acids, cultured cells, viruses and other small molecules (27, 67, 68, 103, 113, 133, 163, 
183, 184, 186, 191, 194). Nucleic acids that bind to the target with higher affinity will 
preferentially associate to form a complex. This complex can be isolated by gel shift, 
nitrocellulose filter binding, or capillary electrophoresis (118). The selected pool is 
expanded by PCR amplification, and the new, enriched pool of nucleic acids is subjected 
to subsequent rounds of target binding. After several rounds, nucleic acids with high 
affinity for the target called “aptamers” are isolated. Aptamers have many potential uses 
in diagnostic and therapeutic applications, such as replacements of antibodies in 
biochemical assays (e.g. ELISA), utilization as biosensors, as a tool for studying the 
molecular biology of virus replication, and development of antiviral drugs (24, 40, 56, 82, 
88, 117, 121, 136, 191). Essentially, any technique that involves sensitive and stringent 
recognition of protein or nucleic acids could benefit from aptamer-based approaches. 
Most aptamers are screened through standard SELEX procedures, which include a 




flanking regions of known sequence at the 5′ and 3′ termini. After selection, the selected 
aptamers often retain sequences from the fixed flanking regions which are required to 
achieve tight binding. Typically, at the end of the selection process, these sequences are 
modified to determine the minimal bases that are required for tight binding. This 
approach poses a disadvantage, where the fixed sequences create biases on the selection 
by interacting with nucleotides in the random region of the selected oligonucleotides.   
Recently, a new “primer-free” SELEX method was developed, where selection occurs in 
the absence of any fixed, flanking nucleotides (125, 127, 184), and a second “minimal 
primer” SELEX, which the fixed sequences are reduced to only a few nucleotides (83, 
177). By eliminating most of the fixed flanking regions in minimal primer SELEX, or by 
removing them entirely in primer-free SELEX during the selection step, these methods 
reduce the biases from the fixed regions. A notable drawback of primer-free approaches 
is that they are more time consuming and include several additional steps. There are also 
steps where bias may be introduced.   
Our lab has introduced a novel primer-free SELEX-based approach for selecting 
single stranded DNA sequences (102). Sequences that bound ~10-fold tighter than the 
starting random sequences to HIV-RT in gel-shift assays were isolated. All the recovered 
sequences had essentially the same sequence, and were characterized by the regular 
arrangement of four separate guanosine doublets in the sequences (5′-
AGGAAGGCTTTAGGTCTGAGATCTCGGAAT-3′, denoted PF1 in this thesis) and a 
predicted secondary structure (∆G = -0.61 kcal/mole, predicted using DNA mfold 
program (197)). The repeated guanosine doublets were also observed in a 15 nt long 




Figure 3-1A) (21, 108). The TBA (5′-GGTTGGTGTGGTTGG-3′) folds into an anti-
parallel G-quadruplex, with two G-quadruplex layers connected by a TGT and two TT 
loops. The HIV nucleocapsid protein has been shown to destabilize the G-quadruplex 
formation of TBA (92). G-quadruplexes are formed by four guanine residues associated 
with one another by Hoogsteen bonds in a square planar configuration. Most monovalent 
cations stabilize G-quadruplex formation by the cation binding specifically to guanine O6 
carbonyl groups between the planes of the G-quartets. The stability is highly dependent 
on the cation size, with K+ or Sr2+ having the most favorable ionic radius at 1.3-1.4 Å, 
while Na+ and Li+ destabilize G-quadruplex formation (156, 169). These structures can 
assume both parallel and anti-parallel configurations and can form between 2 or more 
separate nucleic acid strands (intermolecular), or within the same strand (intramolecular). 
G-quadruplexes have been implicated in several cellular processes including telomerase 
regulation and gene expression (58, 66). 
Several other aptamers to various HIV proteins also are predicted to form G-
quadruplexes. These include aptamers that block HIV envelope glycoprotein gp120 by 
binding to the gp120 cationic V3 loop region (71). Various classes of G-quadruplex 
aptamers were found to inhibit RNase H activity (7, 39), and integrase activity (95). In 
previous studies, Schneider et al. and Michalowski et al. demonstrated a class of HIV-RT 
aptamer with a bimodular structure of a three-tier G-quadruplex and a stem-loop helical 
element (112, 149) (Figure 3-1C and D). In addition to HIV proteins, G-quadruplex 
aptamers to several other viral and non-viral proteins have been selected suggesting that 
G-quadruplexes are a common motif for high affinity protein-nucleic interactions (157).  






Figure 3-1: Secondary structures of various classes of aptamers. (A) Secondary 
structure of Thrombin Aptamer (TBA), model adapted from Kankia et al., Nucleic Acids 
Res. 2005 (92). (B) Predicted structure of 37 NT SELEX from DNA mfold program. The 
run of 7Gs at the 5′ end of the aptamer mimics the polypurine tract (PPT), and prevent the 
formation of other secondary structures, except for the flip-back hairpin loop (43). (C 
and D) Secondary structure of the G-quadruplex aptamers named “R1T” (C) and “S4” 
(D), respectively. Figures adapted from Michalowski et al., Nucleic Acids Res. 2008 




single-stranded DNA derived from primer-free SELEX and denoted above. The central 
diguanosines were crucial for tight binding, and shortening the sequence by as few as 
three nucleotides significantly reduced binding to RT. We also compared the effects of 
several different classes HIV-RT DNA aptamers on RT inhibition. Besides PF1, two 
previously characterized aptamers were also studied: (1) a primer-template flipback 
aptamer developed in our lab that mimics the polypurine tract at the 3′ end of the oligo 
(42, 43) (Figure 3-1B); (2) a G-quadruplex aptamer reported by Michalowski et al. (112). 
PF1 was an effective inhibitor of HIV-RT, however, G-quadruplex aptamer and primer-
template aptamer, both were larger than PF1, were more potent inhibitors. Interestingly, 
based on circular dichroism (CD) analysis, PF1 did not form G-quadruplexes.   
 
3.2 Materials and Methods 
3.2.1 Materials 
Human immunodeficiency virus reverse transcriptase (HIV-RT) was obtained 
from Worthington Biochemical Corporation. Taq polymerase, restriction enzymes and T4 
polynucleotide kinase (PNK) were obtained from New England Biolabs. 
Deoxyribonucleotide triphosphates (dNTPs) were from Roche Applied Sciences. Klenow 
DNA polymerase and dideoxyguanosine triphosphate were from Affymetrix, Inc. 
Radiolabeled compounds were obtained from Perkin Elmer. Sephadex G-25 spin 
columns were from Harvard Apparatus. All oliognucleotides were commercially 
synthesized from Integrated DNA Technologies. All other chemicals were from Sigma-





5′ End-labeling of oligonucleotides with T4 PNK: Reactions for labeling various 
oligos were done in a 50 µl volume containing 25 pmole of the oligo, 70 mM Tris-HCl 
(pH=7.6), 10 mM MgCl2, 5 mM dithiothreitol (DTT), 5 µl of γ-
32P ATP (3000 Ci/mmol, 
10 µCi/µl) and 2 µl (20 units) of T4 polynucleotide kinase. The reaction mixture was 
incubated for 30 minutes at 37oC, and then the PNK was heat inactivated for 10 minutes 
at 70oC according to manufacturer’s recommendation. The material was then run through 
a Sephadex G-25 spin column.   
 
Determination of equilibrium dissociation constants (Kd) with 5′ end-labeled 
substrates: PF1 (~2 nM) from the primer-free SELEX or other designed sequences 
(Table 1) were either labeled internally with α-32P dTTP, or 5′ end labeled with γ-32P 
ATP and mixed with various amounts of HIV-RT in 10 µl of buffer containing 50 mM 
Tris-HCl (pH=8), 1 mM DTT, 80 mM KCl, and 6 mM MgCl2, for 10 min at room 
temperature. Two microliters of 6X native gel loading buffer (40% sucrose, 0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol) was added and the samples were run on a 
6% native polyacrylamide gel (29:1 acrylamide:bisacrylamide) at ~100 V until the blue 
dye marker was ~2-3 inches below the wells. The amount of shifted vs. non-shifted 
material was quantified using a Fujifilm FLA-5100 phosphoimager. Values for Kd were 
determined by plotting the concentration of shifted product (nM) vs. the concentration of 
HIV-RT and fitting the data by nonlinear least square fit to the quadratic equation: [ED] 
= 0.5([E]t + [D]t + Kd) – 0.5(([E]t + [D]t + Kd)
2 – 4[E]t[D]t)
1/2, where [E]t is the total 




where the affinity of HIV-RT for the nucleic acid was low (Kd ≥ 500 nM), a more precise 
Kd value was not determined.   
 
Preparation of substrate for RT inhibition: Sixty pmoles of 50 nt template (5′-TT 
GTAATACGACTCACTATAGGGCGAATTCGAGCTCGGTACCCGGGGATC-3′) and 
50 pmoles of 33 nt 5′ 32P end-labeled primer (5′-TTCCCCGGGTACCCGAGCTCGAAT 
TCGCCCTATAG-3′) were mixed in 20 µl containing 50 mM Tris-HCl (pH=8), 1 mM 
DTT, and 80 mM KCl. The mixture was heated to 80°C for 2 minutes, then cooled at a 
rate of 1°C per minute to 30°C. This material was used directly in the assays. 
 
Preparation of ddG-terminated loop-back substrates: Fifty pmoles of loop-back 
DNA phosphorylated at the 5′ end was incubated with 5 units of Klenow DNA 
polymerase in 50 µl of buffer containing 50 mM Tris-HCl (pH=8), 1 mM DTT, 50 mM 
KCl, 6 mM MgCl2, and 25 µM ddGTP for 30 minutes at 37°C. The material was 
extracted with phenol-chloroform and precipitated with ethanol. The precipitated material 
was run through a Sephadex G-25 spin column to remove any remaining unused ddGTP. 
The concentration of the recovered material was determined by comigration with the 
original substrate and was not extendable by HIV-RT in the presence of dNTPs 
(determined by 5′ end-labeling a portion of the material at low specific activity with γ-32P 
ATP), indicating that it was 3′ terminated with ddG. 
 
RT inhibition assay: Reactions contained substrate (1:1.2 primer:template, final 




containing 50 mM Tris-HCl (pH=8), 1 mM DTT, 80 mM KCl, 6 mM MgCl2, and 0.1 
µg/µl BSA. Various amounts (0.1, 0.5, 1.0 or 5.0 nM of inhibitors for 37 NT Flipback 
(terminated with ddG), R1T and S4, and 25, 50, 100 and 150 nM of inhibitors for PF1 
were used. A 5 µl of a supplement containing 800 µM dNTPs (100 µM final) in the above 
buffer were added to the reactions. The mixture was placed at 37°C for 2 minutes. Primer 
extension was initiated by adding 5 µl of HIV-RT (0.25 nM final concentration in 
reactions). Five microliter aliquots were removed at 2, 5, 10, 15, and 20 minutes and add 
to 5 µl of 2X formamide gel loading buffer (90% formamide, 20mM EDTA (pH=8), 
0.25% xylene cyanol, 0.25% bromophenol blue). Samples were run on a 10% denaturing 
gel as described below and quantified using a Fuji FLA-5100 phosphoimager as 
described above. A graph of the concentration of number of counts (photo-stimulated 
luminescence (PSL) radiation units) vs. time was plotted. The experiment was repeated 
with similar results. The RT inhibition was achieved by a decrease in the concentration of 
available enzyme, being taking up by the aptamer. The half-maximal inhibitory values 
(IC50) were calculated by the relationship between the aptamer concentration and percent 
of inhibition achieved at the particular inhibitor concentration. The concentrations used 
for measured were stated as above, at the 10 min timepoint. A four-parameter logistic 
equation was used for curve-fitting with Sigma Plot software to obtain IC50 for the 
various apatmers: Y = min + [(max-min) / [1+ 10(logEC50-x) Hillslope], where Y is the percent 
of inhibition at a certain inhibitor concentration, and X is the log of the inhibitor 






Circular dichroism spectroscopy: The DNA aptamer samples (see Table 2) were 
heated to 90°C for 2 minutes, then cooled at a rate of 2°C per minute to 30°C. The 
aptamer concentration at 4 µM was adjusted in the corresponding potassium or sodium 
buffers (Potassium buffer final concentration: 50mM Tris–HCl (pH= 8), 80mM KCl, 
6mM MgCl2, 1mM DTT; sodium buffer, final concentration: 50mM Tris–HCl (pH=8), 
80mM KCl, 6mM MgCl2, 1mM DTT). Near-UV circular dichroism (CD) spectra were 
acquired at 25°C using a Jasco J-810 spectropolarimeter (Easton, MD) at 1.0 nm intervals 
between 200 nm and 300 nm in a 1.0 mm quartz cuvette, at a scan speed of 50 nm/min, 
response time at 8 second, and scan sensitivity at 100 mdegrees. 
 
3.3 Results 
3.3.1 Determination of equilibrium dissociation constant (Kd) values for PF1 and the 
SELEX starting material 
In the previous study, Kd values were determined for the PF1 aptamer derived 
from the primer-free SELEX protocol (102) (Chapter 2). Gel-shift analysis was used for 
these determinations as described in Materials and Methods. Since gel-shifts do not 
necessarily reflect equilibrium binding, the determined Kd values are qualitative in nature 
and best used for comparison between the various tested constructs. In the current 
experiments, PF1 had a Kd value of 82 ± 7 nM (Table 3-1, Figure 3-2B). In contrast, the 
random sequence material used to start the SELEX procedure (5′-N30-3′) bound with 




3.3.2 The middle guanosine doublets were required to maintain high affinity to HIV-RT 
PF1 had a striking arrangement of four diguanosine repeats. To test the role of 
these repeats in binding to HIV-RT, several variations of this motif were made. Table 3-1 
summarizes the modifications and lists the determined Kd values for binding to HIV-RT. 
Changing the four guanosine doublets to cytidine (PF1-GG>CC) or adenosine (PF1-
GG>AA) increased the Kd values to > 500 nM, nearly equal to the starting material (5′-
N30-3′). This demonstrated the importance of the diguanosine repeats for tight binding to 
RT. The effects of minor changes in the diguanosine runs were then tested. When the 
guanosine doublets at 5′ and 3′ termini were changed to dicytidine (PF1-terminal 
GG>CC) there was a small increase in the Kd (144 ±10 nM). In contrast, changing the 
two central diguanosines to cytidines led to a dramatic increase in the Kd values to near 
the value for 5′-N30-3′. Changing even one of the two central diguanosines to Cs, or even 
replacing one G nt with a C in one of the central doublets resulted in a significant loss in 
binding affinity (PF1C6-7, Figure 3-2C; PF1-C6 and PF1-C14). These results indicate the 
two central G doublets are pivotal for tight binding to RT while the terminal doublets 
play lesser roles. Interestingly, adding one or two extra guanosine(s) to the central 
doublet closer to the 3′ end also increased the Kd by 2 to 5-fold (PF1-3G, PF1-3G2 (extra 
G added to 3′ central and 3′ terminal diguanosines) and PF1-4G in Table 3-1). The PF1-
4G sequence showed G-quartet formation in gel-shift assay as was evidenced from a 
portion of the construct shifting upward on the gel (Figure 3-2D). This was presumably 
due to the formation of interstrand G-quartets. Finally, a construct that contained the two 
central diguanosine motifs but was truncated at the 5′ and 3′ ends such that the final 












PF1 5′-AGGAAGGCTTTAGGTCTGAGATCTCGGAAT-3′ 82 ± 7  
Diguanosine modifications 
PF1-GG>CC 5′-ACCAACCCTTTACCTCTGAGATCTCCCAAT-3′ > 500 
PF1-GG>AA 5′-AAAAAAACTTTAAATCTGAGATCTCAAAAT-3′  > 500 
PF1-terminal 
GG>CC 
5′-ACCAAGGCTTTAGGTCTGAGATCTCCCAAT-3′  140 ± 10 
PF1-GCmid 5′-AGGAACCCTTTACCTCTGAGATCTCGGAAT-3′  ~ 500  
PF1C6-7 5′-AGGAACCCTTTAGGTCTGAGATCTCGGAAT-3′  ~ 500 
PF1C13-14 5′-AGGAAGGCTTTACCTCTGAGATCTCGGAAT-3′ > 500 
PF1-C6 5′-AGGAACGCTTTAGGTCTGAGATCTCGGAAT-3′ 420 ± 70 
PF1-C14 5′-AGGAAGGCTTTAGCTCTGAGATCTCGGAAT-3′ ~ 500 
PF1-3G 5′-AGGAAGGCTTTAGGGTCTGAGATCTCGGAAT-3′ 310 ± 90 
PF1-3G2 5′-AGGAAGGCTTTAGGGTCTGAGATCTCGGGAAT-
3′ 






















5′-CTGAGATCTCGGAAT-3′  >750 
PF1-
27nt5′cut 
5′-AAGGCTTTAGGTCTGAGATCTCGGAAT-3′ ~ 500 
PF1-26ntG 5′-GGAAGGCTTTAGGTCTGAGATCTCGG-3′  233 ± 29 
PF1-26ntC 5′-CCAAGGCTTTAGGTCTGAGATCTCCC-3′  ~ 500 
PF1-26ntT 5′-TTAAGGCTTTAGGTCTGAGATCTCTT-3′  131 ± 24 
PF1-∆(8-12) 5′-AGGAAGGGGTCTGAGATCTCGGAAT-3′  >750 













PF1-RNA 5′-AGGAAGGCUUUAGGUCUGAGAUCUCGGAAU-3′ >750 
Structural controls 
PF1A 5′-AGGAAGGCAAAAGGAAAAAAAAAAAGGAAT-3′ > 750 
PF1Flip 5′-AGGAAGGCTTTAGGTTTCCTAAAGCCTTCC-3′ 667 ± 144 





PF1T 5′-TGGTTGGTTTTTGGTTTTTTTTTTTGGTTT-3′ 448 ± 25 
1For experiment 1 names indicate the round of selection from which the sequence 
was recovered followed by a designated number.  
2The repeated diguanosines were denoted in blue for PF1 and its variants. The 
modifications on the constructs were denoted in red. The RNA analog (PF1-RNA) 
of PF1 was also showed in the “Truncated constructs” section. 
3Equilibrium dissociation constants (Kd) were determined using a gel shift assay as 
described under Material and Methods. Results for PF1 are an average of 3 
experiments ± standard deviation. The result for the starting material (5′-N30-3′) 
and the constructs were estimates based on 3 repeated experiments. 
 







Figure 3-2: Gel-shift analysis of the aptamer PF1 and its various constructs. 
Increasing amounts of HIV-RT (as indicated above wells) were mixed with 5′ 32P end-
labeled PF1 (Figure 3-2B) or the constructs as described in Methods. Samples were run 
on a native 6% polyacrylamide gel. Positions of shifted and unshifted material are 
indicated. Figure 3-2D: G-quartets (G-quart, boxed lanes) were observed migrating 




indicated that the central diguanosines alone cannot confer high affinity binding to RT. 
 
3.3.3 Truncations of the aptamer abolished its tight binding to HIV-RT  
The length of the selected aptamer was also tested as a potential factor for tight 
binding. Table 3-1 showed the various oligos that were designed by progressively 
eliminating nucleotides from the termini of the 30 nt PF1. As few as a three nucleotide 
deletion at either the 5′ end increased the Kd approximately 6-fold. Deleting ten to fifteen 
nucleotides resulted in an even greater loss of affinity to essentially the level of 5′-N30-3′ 
(Figure 3-2A). Similarly, when the nucleotides in between the guanosine doublets were 
eliminated (PF1-∆(8-12), PF1-∆(16-25), PF1-∆(8-12/16-25), and PF1-18ntTlinkG 
(closely resembles TBA aptamer), the shortened oligo lost its ability to bind RT tightly. 
All of these constructs showed Kd comparable to 5′-N30-3′. These results indicate that 
PF1’s high affinity for RT is highly dependent on the length of the oligo, as the binding 
of RT significantly decreases even when three nucleotides were trimmed off. However, it 
is important to point out that the truncations discussed above eliminate at least one of the 
4 diguanosine motifs. Therefore they do not completely separate the role of the 
diguanosine repeats vs. nt length in achieving strong binding to HIV-RT. To test this 
further, a construct 1 and 3 nts eliminated from the 5′ and 3′ termini, respectively, was 
tested (PF1-26ntG). This construct retains all 4 diguanosines but was shortened by 4 nts. 
This resulted in about 3-fold increase in the Kd in comparison to PF1. The role of the 
terminal diguanosines was further evaluated by changing the diguanosine in PF1-26ntG 
to either dicytidines (PF1-26ntC) or dithymidines (PF1-26ntT). While dicytidine had a 




positive effect. Overall, these results suggest a complex interaction between RT and the 
constructs and a critical role for the central diguanosines. Beyond this, length and nt 
sequence at the termini play some role in high affinity binding but are less vital.   
 
3.3.4 An RNA version of PF1 does not confer tight binding to HIV-RT 
An RNA analog of the 30 nt PF1 aptamer (PF1-RNA) was tested for RT binding. 
PF1-RNA did not bind with high affinity to RT indicating that high affinity interaction 
was specific to DNA (Table 3-1).   
 
3.3.5 The diguanosine repeats require the specific sequences in PF1 to retain HIV-RT 
tight binding 
The strucutural component of the sequences between the diguanosine repeats in 
PF1 was also tested. Table 3-1 showed the various constructs designed with a low 
structure between the diguanosine repeats, where the sequence is entirely made of As and 
Ts (PF1A, PF1T) to prevent any formation of a higher structure. A random sequence 
retaining the G repeats (PF1N) was tested as well. Two higher structure constructs were 
made: PF1Flip contained a flipback structure in the presence of three of the diguanosine 
repeats; PF1 loop had a hairpin-loop structure in between the middle diguanosines. 
Despite the structural differeneces, all of the constructs had Kd values increasing 
approximately 6-fold or even more in comparison to PF1 (Table 3-1). The structure of the 
constructs in fact played little role in the tighter binding; for example PF1A had a Kd 




have essentially no secondary structure, similar to the very low structure of PF1, yet they 
bind poorly.  
 
3.3.6 The selected aptamer PF1 can inhibit HIV-RT primer extension, but not as 
effectively as some other previously characterized RT aptamers 
An HIV-RT primer extension assay was performed to determine whether the 
selected aptamer PF1 could effectively inhibit HIV-RT in vitro. A 33 nt 5′ 32P end-
labeled DNA primer was hybridized to a 50 nt template (50 nM final concentration, 
complex shown in Figure 3-3). HIV-RT utilizes this primer-template to extend the primer 
portion towards the 5′ end of the template. Assays were performed using 50 nM primer-
template and 0.25 nM HIV-RT and the amount of extended primer was measured over a 
time course from 2-20 min (Figure 3-4). Results were plotted (relative counts vs. time) 
and used to calculate the half-maximal inhibitory value (IC50) as described Material and 
Methods. The IC50 of PF1 was 63 ± 24 nM. This concentration is comparable to the 
primer-template concentration used in the experiment, suggesting that PF1 binds 
approximately as well as the primer-template. The IC50 for 5′-N30-3′ was > 500 nM 
(Figure 3-5, Table 3-2). Interestingly, even those oligos that showed only modestly lower 
affinities for RT in the gel-shift assays (PF1-26ntT and PF1-terminal GG>CC) were poor 
inhibitors of RT extension relative to PF1.  
As a comparison, we used a class of G-quadruplex RT aptamers studied by the 
Michalowski et al. that were potent inhibitors of HIV-RT (112). The main G-quadruplex 
aptamer, known as “R1T”, was a 41 nt oligo with a three tier parallel G-quadruplex 








5′-NNNNNNNNNNNNNNNNNNNNNNNNNNNNN-3′ > 500 












0.9 ± 0.3 
S4 5′-CGCCTGACCCTTCAGGCGTTGGGTGGGTGGGTGGG-3′ 0.5 ± 0.1 










5′-TTAAGGCTTTAGGTCTGAGATCTCTT-3′ > 250 
1Nucleotides in bold indicate the region which forms G-quadruplexes. The underlined 
portion indicated the polypurine tract-like sequence in the primer-template aptamer. 
2The IC50 were determined using a RT inhibition assay as described under Material 
and Methods. Results for the experimental and control oligonucleotides were an 
average of 3 experiments ± standard deviation. The results for the starting material 
were estimates based on 3 repeated experiments.  
 





Figure 3-3: A schematic representation of the primer-template used in the RT 




Figure 3-4: A representative autoradiogram using various concentrations of PF1. 
The assay was conducted by incubating the primer-template (50 nM 5′ γ-32P end-labeled 
primer) with 100 µM dNTPs and various concentrations of aptamers as indicated. 
Reactions were initiated with HIV-RT (0.25 nM), and aliquots were removed at 2, 5, 10, 
15 and 20 minutes. The samples were run on a denaturing 10% polyacrylamide gel and 
quantified as described in Materials and Methods. The IC50 determination of PF1 was 






Figure 3-5: Graph showing the relative counts versus time in the presence of various 
amounts of PF1 or starting material (5′-N30-3′). The number of counts is defined as 
photo-stimulated luminescence (PSL) radiation unit measured. The assay was conducted 
by incubating the primer-template (50 nM 5′ γ-32P end-labeled primer) with various 
concentrations of aptamers and dNTPs. Reactions were initiated with HIV-RT (0.25 nM), 
and aliquots were removed at the indicated times. The samples were run on a denaturing 




modifications to the stem-loop component, while retaining the G-quadruplex structure 
(Figure 3-1D). Consistent with the previous results, both the R1T and S4 aptamers were 
potent inhibitors in the RT extension assay used here with IC50s of 0.90 ± 0.33 nM and 
0.54 ± 0.12 nM, respectively (Table 3-2; Figures 3-6 and 3-7 respectively). 
Our lab developed a unique primer-template flipback aptamer, “37 NT SELEX”, 
which is a 37 nt long single strand DNA, and a potent inhibitor of HIV-RT (42, 43) (see 
Introduction, Figure 3-1C). For the RT inhibition experiments, the primer-template 
aptamer had the terminal 3′ guanosine residue replaced with a dideoxyguanosine (ddG) to 
prevent extension by HIV-RT. Consistent with previous results, 37 NT SELEX was an 
effective inhibitor with an IC50 of 3.7 ± 1.1 nM (Table 3-2, Figures 3-6 and 3-7). 
 
3.3.7 Circular dichroism spectroscopy indicates the selected aptamer does not form a G-
quadruplex 
Circular dichroism (CD) spectroscopy is an analytical tool for detecting secondary 
structures and G-quadruplexes in DNA. The characteristic feature of a G-quadruplex is a 
distinctive positive band at 210 nm, between 260-265 nm, and a negative peak at ~240 
nm. For antiparallel quadruplexes, the negative peak is at ~260 nm, and a positive peak at 
~290 nm. A regular B-DNA has a negative peak at 210 nm and ~ 240 nm, plus a positive 
peak at 220 nm and between 270-280 nm (101) (Figure 3-8). For single-stranded DNA 
sequences, the CD spectrum is similar to the spectrum for the double-stranded DNA with 
the same coding strand sequence (76). A hairpin loop DNA “flips-back” onto itself to 
form an intramolecular B-DNA (101).  





Figure 3-6: Graph indicating the relative counts versus time in the presence of 
various amounts of R1T and 37 NT SELEX ddG. The number of counts is defined as 
photo-stimulated luminescence (PSL) radiation unit measured. The 37 NT SELEX 
aptamer contained a 3′ terminal dideoxy G residue in place of the normal dG to prevent 
extention of the aptamer itself. The assay was conducted by incubating the primer-
template (5′ γ-32P end-labeled primer, 50 nM) with various concentrations of aptamers 
and dNTPs. Reactions were initiated with HIV-RT (0.25 nM), and aliquots were removed 
at the indicated times. The samples were run on a denaturing 10% polyacrylamide gel 






Figure 3-7: Graph indicating the relative counts versus time in the presence of 
various amounts of S4 and 37 NT SELEX ddG. The number of counts is defined as 
photo-stimulated luminescence (PSL) radiation unit measured. The 37 NT SELEX 
aptamer contained a 3′ terminal dideoxy G residue in place of the normal dG to prevent 
extention of the aptamer itself. The assay was conducted by incubating the primer-
template (5′ γ-32P end-labeled primer, 50 nM) with various concentrations of aptamers 
and dNTPs. Reactions were initiated with HIV-RT (0.25 nM), and aliquots were removed 
at the indicated times. The samples were run on a denaturing 10% polyacrylamide gel 





Figure 3-8: A generalized circular dichroism (CD) spectrum of B-DNA and parallel 
G-quadruplex with the presence of potassium ions. The B-DNA spectrum was shown 
in black, while the spectrum for the parellel G-quadruplex was shown in red. The anti-
parallel G-quadruplex has a negative peak at ~265 nm and positive peaks at ~210 and 295 




(Figure 3-1A) contained positive peaks at 210 and 295 nm, and a negative peak at 265 
nm in Figure 3-9, confirming its antiparallel G-quadruplex nature (108). R1T showed 
positive peaks at 210 and 260 nm, and a negative peak at 240 nm at room temperature in 
the presence of potassium, indicating R1T is a parallel G-quadruplex. While potassium 
stabilizes G-quadruplex formation, sodium disfavors formation (156, 169). Figure 3-10 
showed R1T retained its G-quadruplex structure (even the spectrum is slightly flattened) 
in the presence of 80 mM NaCl, while the TBA G-quadruplex structure was disrupted 
under these conditions (142, 156, 169). The retention of quadruplex structure by R1T in 
the presence of Na+ likely reflects the high stability of this particular quadruplex (112). 
PF1 showed a positive peak at ~270 nm and a negative peak at ~240 nm as well as a 
positive peak at 220 nm, and negative peak at 210 nm, indicating PF1 did not form a G-
quadruplex. The constructs with the guanosine doublets substituted (PF1-GA, PF1-GC, 
see table 3-1) were compared with PF1 by CD measurement and yield a spectrum similar 
to PF1. A 37 nt Linear DNA Control was also tested to observe the CD spectrum of a 
linear single-stranded DNA in the presence of potassium ions. All modified constructs 
and the 37 nt Linear DNA Control had patterns close to that of the PF1 in the CD 
spectroscopy, indicating that the PF1 and the various constructs did not form 
intramolecular G-quadruplexes (Figure 3-11).  
 To study the CD spectra of single-stranded DNA sequences with different levels 
of structure, several single-stranded DNA constructs were measured. These included PF1, 
the G-quadruplex aptamer R1T, homopolymeric 30-mers composed of A (5′-dA30-3′ in 
Chapter 2, dA30 in Chapter 3) or T (5′-T30-3′ in Chapter 2, T30 in Chapter 3) which 







Figures 3-9 & 3-10: CD spectra of 4 µM of PF1, R1T, starting material (5′-N30-3′) 
and TBA. Aptamers in Figures 3-9 and 3-10 were measured in potassium and sodium 




and a highly structured 30 nt G-C rich sequence (G-C flip-back, see Figure 2-5A in 
Chapter 2). The PF1 aptamer and the various DNA constructs (with the exception of 
dA30, see below) showed similar CD spectra (Figure 3-12). Note that dA30 (5′-dA30-3′), 
showed a sharp positive and negative peak at 220 and 210 nm, respectively, which is a 
characteristic trait of poly [d(A)] DNA sequence (101). Consistent with previous results, 
R1T retained a CD spectrum for DNA forming a parallel G-quadruplex. 
 
3.4 Discussion 
3.4.1 Effects of the guanosine repeats on HIV-RT binding and possible structures of PF1 
In this study, we characterized a group of single-strand DNA aptamers to HIV-RT 
that were isolated using a novel primer-free SELEX technique (102), and defined 
whether the aptamer affinity to RT was dependent on its length, sequence or structure. 
We speculated that the regular arrangement of four separate diguanosines in the 
sequences affect the tighter binding of the selected aptamer to HIV-RT. This prediction 
was based on this arrangement in aptamers isolated from two separate SELEX 
experiments (Chapter 2). The likelihood of such a specific sequence occurring arbitrarily 
in two separate SELEX experiments let alone in a single selection is highly unlikely. 
Although it is possible that the diguanosine array resulted from the unique SELEX 
protocol used to select the aptamers (see Chapter 2), the fact that the selected aptamers 
bind much more tightly to HIV-RT than the SELEX experiment starting material strongly 
suggests that their selection was based on affinity to RT. It could also be argued that the 
low predicted secondary structure of PF1 was at least in part due to the Thermostable 







Figure 3-11: CD spectrum of 4 µM of PF1, PF1-GA, PF1-GC and 37 nt Linear DNA 
Control, and Figure 3-12: CD spectrum of 4 µM of PF1, T30, R1T, 37 NT SELEX, 
G-C Flipback and dA30. The various constructs were measured in potassium buffer, as 




structured aptamers from being selected. However, results showed that only strong 
secondary structure led to inefficient ligation (102) (Chapter 2). The low secondary 
structure of PF1 may permit it to more easily conform to RT and maximize binding. The 
low structure could provide flexibility that allows the diguanosines to be positioned for 
optimal binding to RT or formation of a G-quadruplex. However, low structure alone 
clearly cannot account for PF1’s affinity to RT as oligo’s with even lower predicted 
structure and identical diguanosine spacing bound RT poorly (PF1A, and PF1T). 
Therefore, PF1’s strong binding results at least in part from the specific sequence 
inbetween the diguanosine repeats, even though those sequences presumably generate 
little structure. Other results suggested that low structure was a factor in tight binding to 
RT. When a loop structure was placed between the middle diguanosines (PF1Loop), or 
PF1 is modified into a flip-back DNA (PF1Flip), both constructs did not bind tightly to 
HIV-RT, even though their sequences are close to the PF1. Overall the results suggest the 
interaction between PF1 and HIV-RT is complex and may be driven by diguanosine 
repeats optimally spaced by specific sequences that generate little structure.       
The diguanosine repeats in PF1 were similar to those found in intramolecular G-
quadruplex forming aptamers that bind tightly to other proteins (108, 112). In addition, 
G-quadruplex forming aptamers have been shown to bind HIV-RT and many other 
proteins with high affinity (see Introduction). Surprisingly, CD spectroscopy indicated 
PF1 did not form a G-quadruplex (Figure 3-9). This does not necessarily rule out the 
possibility of PF1 forming G-quadruplexes or other higher order structures, since both the 
low and high structure constructs all showed similar CD spectra (Figure 3-12). The 




aptamer leading to G-quadruplex or other structural formation. If this were the case, and 
assuming quadruplex formation is required for tight binding, then changes in any of the 
four guanosine doublets would be expected to be highly detrimental to RT binding. 
Changing any doublets did decrease binding but the two central doublets were clearly 
more important as changes in these had a profound affect on RT affinity (Table 3-1). 
PF1-terminal GG>CC, which changes the diguanosines at the termini to Cs showed just a 
modest decrease in binding. PF1-26ntT which changed the terminal Gs to Ts and also 
deleted the flanking terminal nucleotides similarly showed a small change in binding. It is 
important to reiterate, however, that gel-shift is not a highly quantitative method for 
measuring affinity. Consistent with this, PF1-26ntT and PF1-terminal GG>CC were 
much weaker inhibitors than PF1 in the RT extension assay (Table 3-2) despite the small 
changes observed by gel-shift. To clearly determine whether G-quadruplex formation is 
important to PF1’s interaction with RT, structural analysis using nuclear magnetic 
resonance (NMR) or X-ray crystallography would be required.     
 
3.4.2 The role of the aptamer length to HIV-RT tight binding 
Although PF1 demonstrated ~10-fold tighter binding to RT than the starting 
material, deletion of just a few nucleotides caused a significant decrease in binding 
(Table 3-1). Even PF1-26ntG which retains all the diguanosines and intervening 
sequences, but lacked 1 and 3 nts from the 5′ and 3′ ends, respectively, showed a modest 
loss in binding. Any changes that eliminated or changed the spacing between diguanosine 
runs essentially eliminated tight binding. From these results it appears that there may be 




requirement for the diguanosine. The second point is strengthened by the two separate 
SELEX experiments that selected aptamers with identical diguanosine spacing (Chapter 
2) (102). In fact the entire sequence of the selected material from each experiment was 
very similar with typically just 1-2 nucleotide differences in each sequence in comparison 
to PF1. This also suggests that there is sequence specificity for non-diguanosine bases as 
well. With respect to length, DNA aptamers to HIV-RT reported in the literature are 
typically larger than PF1. The 37 nt and 35 nt aptamers (37 NT SELEX and S4, 
respectively) used in the inhibition studies here are among the shortest reported for 
aptamers that bind in the nM range (Table 3-2). Perhaps 30 nts is approaching the limit 
required to obtain low nM binding for a DNA aptamer. In contrast RNA aptamers of ~ 30 
nts that form pseudoknots can bind RT with very high affinity (pM binding constants are 
reported) (96). We are currently attempting to select larger and smaller DNA aptamers 
than PF1 using the primer-free SELEX method. This should help determine the 
importance and limitations of aptamer length.  
 
3.4.3 Comparison between various classes of aptamers in HIV-RT inhibition assays 
HIV-RT and other DNA polymerases utilize a primer-template duplex as their 
natural substrate. In an RT extension assay, the HIV-RT aptamers can compete with the 
primer-template complex as has been shown for 37 NT SELEX and the R1T and S4 G-
quadruplex aptamers used here (42, 43, 112). The G-quadruplex inhibitors were the most 
potent with IC50 values that were ~ 5 fold lower than 37 NT SELEX, which was also a 
potent inhibitor. It is notable that the G-quadruplex inhibitors seem to bind even more 




though PF1 did not inhibit as well as the other aptamers, the determined IC50 value (63 ± 
24 nM) indicated that it still bound approximately as tightly as the primer-template used 
in the assays. Such tight binding would not be predicted for a single stranded B-form 30-
mer with very low predicted structure. The possibility that PF1 was forming a loop-back 
type structure or dimerizing to form a primer-template was investigated. Folding and 
hybridization programs did not predict any of these structures and no extension of PF1 
was observed in assays with HIV-RT and dNTPs (data not shown). This suggests that no 
3′ recessed termini was formed.      
The stronger inhibition observed here and tighter binding reported for 37 NT 
SELEX and the G-quadruplex aptamers indicates that these aptamers bind with 
significantly greater affinity to RT than PF1. There are several possible reasons for this 
including the different SELEX protocols used, the length of the aptamers, and the 
extensive post-SELEX modifications of the 37 NT SELEX and the G-quadruplex 
aptamers. For example, the 37 NT SELEX binds ~10 fold better than the aptamers 
selected from the original SELEX (112) while the G-quadruplex aptamers used here are 
about twice as potent in inhibition assays as the parent aptamers from which they were 
derived (112). With respect to length, when 37 NT SELEX was reduced to only 27 nt, its 
Kd increased by a 100-fold, even though the run of 7Gs was still present (43). Similarly, 
the shortest G-quadruplex aptamer was 35 nt, and it required the stem-loop component to 
achieve tight binding to HIV-RT (112, 149). It will be interesting to see if PF1 can also 





3.4.4 Applications and future work 
The HIV-RT aptamers tested here were derived from various SELEX protocols 
including a traditional protocol for the G-quadruplex aptamers, and two protocols 
developed in this lab: one that selects “primer-templates” for 37 NT SELEX (42), and a 
second primer-free protocol for PF1 (102). Aptamers derived from each protocol had 
unique properties with respect to sequence and structure. In particular the primer-free 
SELEX generated low structure aptamers although it was not entirely clear if this is a 
general property of this protocol or was specific to HIV-RT. The protocol includes a step 
with Thermostable RNA Ligase that was sensitive to structure, but only when the 
substrates for ligation were highly structured. Presumably this step could be modulated to 
help regulate the structure of the aptamers that are selected. This could be done by 
lowering the ligation temperature (60°C in the standard protocol) or shorting the time 
allowed for ligation, both which would favor aptamers with lower structure. The low 
structure aptamers may not bind as tightly to their target as aptamer binding is often 
structure-dependent, however, they may have other advantages, particularly as models for 
the development of cellular inhibitors. It is known that highly structured nucleic acids 
tend to elicit innate immune responses in cells (70). Low structure aptamers may 
overcome such cellular response, and also facilitate possible couplings of delivery 
systems for entry into the cell. Both G-rich oligonucleotides and those that can form G-
quartets have effects on cells ranging from induction of senescence and aging (141), to 
inhibition of proliferation (33, 34, 148). G-quadruplexes are also associated with 
inhibitory cellular properties, via the oligos presumably binding to nucleolin (41, 62), 




these properties could be valuable tools for the development of oligonucleotide therapies 
in the future.  
The primer-free SELEX I developed is a powerful technique for isolating unique 
aptamers for HIV-RT; the significance of this primer-free SELEX technique lies in the 
reduction of biases, the relative ease in the selection process, and the selection of a 
unique set of aptamers for HIV-RT. However, it does not replace the traditional SELEX 
or other SELEX techniques. It will still be important to use multiple SELEX approaches 
to generate different classes of aptamers, since there are still values on the other methods 
for aptamers screening. For example, aptamers with lower structure may be more useful 
as models for cellular inhibitors, while those that bind very tightly to the target protein 
may be more useful in diagnostic applications. Nevetherless, the primer-free SELEX 
technique I developed is a powerful tool for potential small-molecule based drug and 




Chapter 4: Effects of primer-template aptamers to HIV-RT on 
inhibition of HIV replication in cell culture 
4.1 Introduction 
HIV-RT and several other proteins, even those that are not typical nucleic acid 
binding proteins, have been shown to bind strongly to particular RNA and DNA 
sequences, often based on the secondary and tertiary structures the sequences form (172, 
173). These tight binding sequences - aptamers - are synthetic, single stranded nucleic 
acids with unique three-dimensional structures, allowing the folded sequence to bind 
specifically to the target protein (137). Aptamers are mainly produced by a process called 
Systematic Evolution of Ligands by EXponential enrichment (SELEX), which was 
discovered independently by the Gold, Szostak, and Joyce labs (49, 90, 172). The Gold 
lab used SELEX to isolate short RNA sequences as high-affinity ligands to HIV-RT 
(172). The first aptamers isolated for HIV-RT were RNAs with pseudoknot-type 
structures (173). RNA pseudoknot aptamers have been shown to be potent RT inhibitors 
by interfering with primer-template extension by RT (28, 65, 81). Later SELEX was also 
used to select for single stranded DNA aptamers with similar properties of RT inhibition 
(118, 149). Tight binding to RT is mainly determined by the folded structure of the 
aptamer instead of aptamer sequence. These aptamers typically bind several-fold more 
tightly than the natural RT substrate (RNA-DNA or DNA-DNA primer-template) and 
show high affinity for RT (65, 96). Since aptamer binding depends on multiple contacts 
with RT amino acids, it is suggested that aptamers would induce fewer mutants that are 




are recent reports of RT aptamer escape mutants (53, 89), however these escape mutants 
were replication defective in comparison to wild type virus. 
SELEX has enabled researchers to select for aptamers that binds to several HIV 
proteins and targets for other diseases (24, 56, 65, 82, 88, 99, 109, 111). Many of these 
aptamers are currently being developed as potential treatments for diseases. Other non-
therapeutic uses for aptamers are also being explored including their uses as alternatives 
to antibodies, diagnostic biosensors (known as aptamer beacons), and as a tool to study 
the mechanisms of viral replication (40, 82, 136). Currently the only Food and Drug 
Administration (FDA) approved aptamer-based drug is Macugen, which was developed 
by EyeTech Pharmaceuticals and is used to treat age-related macular degeneration 
(AMD) by injecting the drug to the center of the retina (121). The reason why there are so 
few aptamer-based drugs is due to the limited success in human therapeutics (130). The 
main disadvantage of DNA aptamer therapy is the lack of an effective method for 
delivering the inhibitor to target cells in animal models, especially since host nucleases 
may degrade the inhibitor before it is able to bind to the target protein. Modified sugar 
and thiophosphate backbones can help protect against degradation, and the potential use 
of gene vectors for delivery of RNAs is being explored (24, 56). A new approach where 
oligonucleotides are anchored to small proteins to cargo the protein-nucleic acid complex 
across the cell membrane is also promising for both RNA and DNA aptamers and other 
types of nucleic acid inhibitors (171). Recent research suggests that aptamers can enter 
cells during viral infection without transfection or conjugation to cargo proteins (110, 




virus was able to inhibit viral infection not only in mouse cells, but also when 
administered to infected mice in vivo (110).  
Though currently limited as therapeutics due to cost and a lack of delivery 
systems, aptamers still hold a great deal of promise. Potential uses include not only 
targeting specific pathogen proteins, but also host proteins involved in pathogenesis. In 
such, aptamers should be useful in helping to define the potential efficacy of both 
pathogen and host targets. The possibility of therapeutic use should not be overlooked, 
especially considering that drug-delivery systems research is a highly active field. 
Moreover, the study of aptamers could help us to understand the interaction between RT 
and the different nucleic acid substrates. The structural information gained from this 
could set the stage for developing small molecule inhibitors that would be useful in HIV 
treatment.  
Our lab has recently used a unique SELEX technique to show that HIV-RT can 
bind with high affinity to specific primer-template sequences (42). Based on these 
sequences, which resembled the HIV polypurine tract (PPT), DNA aptamers that 
demonstrate tight binding and inhibition of HIV RT in vitro were developed (43). Our 
results showed that the aptamers and controls with the flipback structures caused HIV 
replication inhibition, while less structured controls did not effect replication. The 
flipback structure controls bound RT in vitro with much lower affinity than the flipback 
aptamer while inhibition of replication in cells was essentially equal. This suggests 
inhibition may not have resulted from binding to RT but was due to other factors such as 
activation of cellular pathways. Previous studies have shown that nucleic acids can 




turn induces tetherin (BST-2) expression in cells which can inhibit virus replication (8). 
BST-2 is a 30-36 kD transmembrane protein that traps fully mature HIV-1 virus particles 
on the surface of infected cells (120). HIV conteracts BST-2 inhibition with Vpu (176). 
The effect of the aptamer inducing interferon, and subsequently BST-2 expression was an 
aspect we considered. We did not find any evidence of a correlation between tetherin 
induction and the presence of aptamers or flipback controls used in this study. This does 
not rule out the possibility that interferon or other cellular pathways may cause HIV-1 
inhibition in cell culture. 
 
 4.2 Materials and Methods 
4.2.1 Materials 
Human immunodeficiency virus reverse transcriptase (HIV-RT) was from 
Worthington Biochemical Corporation. dNTPs were from Roche Applied Sciences. 
Klenow DNA polymerase and dideoxyguanosine triphosphate were from Affymetrix, 
Inc. Radiolabeled compounds and britelite plus Reporter Gene Assay System kits were 
obtained from PerkinElmer, Inc. All oliognucleotides were commercially synthesized 
from Integrated DNA Technologies. Sephadex G-25 spin columns were from Harvard 
Apparatus. Fetal bovine serum (FBS) was from Aleken Biologicals. Jurkat E6-1 clone 
cell line was obtained from American Type Culture Collection (ATCC). TZM-bl cell line 
and anti-human BST-2 antibodies (diluted at 1:5000) (114) were obtained from the AIDS 
Research and Reference Reagent Program, National Institutes of Health (NIH). 
Horseradish Peroxidase (HRP)-conjucated goat anti-rabbit IgG antibodies (diluted at 




from Thomas Scientific, Inc. Enhanced chemiluminescence (ECL) Western blotting 
detection system and ECL DualVue Western blotting markers were obtained from GE 
Healthcare Bio-Sciences Corp. CellTiter 96 AQueous One Solution Reagent was from 
Promega, Inc. P24 antigen capture enzyme-linked immunosorbent assay (ELISA) kits 
were provided by SAIC-Frederick, Inc. Vectashield mounting medium was from Vector 
Laboratories, Inc. All other chemicals and media were from Sigma-Aldrich Co., Thermo 
Fisher Scientific, Inc., Lonza Group, Ltd., or VWR Scientific.  
 
4.2.2 Methods 
Effects of various aptamers on Jurkat cell proliferation: Jurkat clone E6-1 cells 
were washed with RPMI complete media (10% FBS, 1x Pen-Strep (Penicillin: 50 IU/mL, 
Streptomycin: 50 µg/mL) in RPMI-1640). Jurkat cells (50 µl of 5 x 104 cells/ml per well) 
were plated into a 96-well plate. Various aptamers at their respective concentrations (50 
µl each) were added into the cells. The cells were incubated for 48 hours at 37°C, with 
5% CO2 and 95% humidity. After the 48 hours incubation, 20µl of CellTiter 96 AQueous 
One Solution Reagent was added to each well. The cells were incubated at 37°C for 45-
60 minutes in 5% CO2, 95% humidity. The absorbance of the samples was recorded using 
a 96-well plate reader at 450 nm. For the trypan blue dye exclusion method, Jurkat cells 
(100 µl of 1 x 105 cells/ml per well) were plated into a 96-well plate. Various aptamers at 
their respective concentrations (100 µl each) were added into the cells. The cells were 
incubated at 37°C, with 5% CO2 and 95% humidity. Cell growth were monitored each 
day for 10 days by mixing equal volumes (15 µl) of each cell sample and trypan blue dye. 




HIV-1 inhibition with various aptamers on Jurkat cells: Jurkat clone E6-1 cells 
were washed with RPMI complete media as described above. Jurkat cells (at 1 x 105 
cells/well) were infected with HIV-1 LAI virus at MOI = 0.01, or mock-infected with 1x 
phosphate-buffered saline (PBS). Cells were plated in a 24-well plate, with a total volume 
of 150 µl in a 24-well plate. Incubation conditions were at 37°C, 5% CO2 and 95% 
humidity for 2 hours. The infected cells were pelleted and washed with the RPMI 
complete media (see above) for two times. The cells were resuspended in 300 µl of the 
RPMI complete media. Various concentrations of the each aptamer and the controls (0, 1, 
2 and 4 µM) were added to the cells, to make up a total of 600 µl in a 24-well plate. The 
cells were incubated at 37°C, 5% CO2 and 95% humidity. Aliquots (20 µl per sample) 
were taken on 5, 6 and 7 days post infection (dpi) and replaced with an equivalent 
concentration of aptamer. 
 
Limiting-dilution assay to quantify infectious virus produced from various 
aptamers: Limiting-dilution assay were performed using five-fold serial dilutions from 
aliquots obtained above, with the initial viral dilution at 1/500. Fresh Jurkat cells (2.5 x 
104/cells per well, 200 µl total volume) were infected with the diluted virus, with 3 
separate infections for each dilution. The cells were incubated on a 96-well plate, at at 
37°C, 5% CO2 and 95% humidity for 5 days. P24 antigen capture enzyme-linked 
immunosorbent assays (ELISA) were performed on the infected cell supernatant 
(methods are described in the manual provided by SAIC-Frederick Inc.). The plates were 
read at 450 nm with a 96-well microplate reader. The TCID50/ml was calculated by 




mathematical equation, provided by the Mullins lab, University of Washington School of 
Medicine. Limit-dilution assays were also performed by infecting TZM-bl cells (obtained 
from the NIH AIDS Research and Reference Reagent Program) to test the aptamer 
inhibition during HIV replication. TZM-bl cell line is a HeLa cell derivative with a HIV-
1 tat promoter upstream of a luciferase reporter and a beta-galactosidase reporter. The 
cells were treated with 20 µg/ml of DEAE-dextran prior adsorption to increase sensitivity 
of the cells to HIV-1. The cells will be infected with viral aliquots diluted in DMEM 
supplemented with 10% FBS and 1x Pen/Strep. At 48 hours post infection, the cells were 
washed once with 1x phosphate-buffered saline (PBS). The Britelite plus Reporter Gene 
Assay System was added to the samples according to the manufacturer’s instructions. 
The plates were read with the Centro XS3 LB 960 Microplate Luminometer from 
Berthold Technologies, and results were recorded with the MikroWin 2000 software. 
 
Determining aptamer cell entry with the presence or absence of virus: Jurkat 
clone E6-1 cells were washed with RPMI complete media as described above. Jurkat 
cells (at 1 x 105 cells/well) were infected with HIV-1 LAI virus at MOI = 0.1, or mock-
infected with 1x PBS. Cells were plated, incubated, and washed as above. The cells were 
resuspended in 300 µl of the RPMI complete media. Various concentrations of the 
fluorescein-tagged aptamer (0, 0.5, 1, 2 and 4 µM) were added to the cells (total volume 
600 µl) in a 24-well plate. The cells were incubated on a 96-well plate, at 37°C, 5% CO2 
and 95% humidity for 48 hours. The cells were washed once in 1x PBS, then fixed in 4% 
formaldehyde, 10 minutes at room temperature. The fixed solution was removed, and 




was applied to the cells at 1 µg/ml, and incubated at 37°C for 10 minutes. The cells were 
washed three times, and resuspended in 10 µl Vectashield mounting medium. The 
resuspended cells were place on a glass slide, and sealed with a cover slip. The cells were 
analyzed using an epifluorescence microscope at 400x total magnification.  
 
Immunoblot analysis on BST-2 expression in cells with the presence of aptamer: 
Jurkat clone E6-1, CEM-SS and 293 cells were washed with RPMI complete media (or 
DMEM complete media for 293) as described above. Cells (5 x 105 cells/sample) were 
resuspended in 300 µl of the RPMI or DMEM complete media. Various concentrations of 
the aptamer and its controls (0 and 2 µM) were added to the cells, to make up a total of 
600 µl in a 24-well plate. The cells were incubated at 37°C, 5% CO2 and 95% humidity 
for 48 hours. The cells were washed once in 1x PBS, then resuspended in 80 µl PBS (~ 2 
x 106 cells/sample). The 80 µl cells were mixed with of with an equal volume of 2X 
Laemmli buffer [4% SDS, 125 mM Tris-HCl (pH=6.8), 10% 2-mercaptoethanol, 10% 
glycerol, 0.01% bromophenol blue]. The mixture was incubated the mixture at 95 °C for 
10–15 min. The denatured cell lysates (15 µl), along with 5 µl of the DualVue molecular 
marker were run on a SDS-PAGE (5% stacking gel and 10% separating gel). The protein 
gel was transferred onto a nitrocellulose membrane with a transfer apparatus with 30 V at 
4°C overnight. A blocking solution [5% nonfat milk in 1x TBST (50 mM Tris (pH=7.5), 
150 mM NaCl, 0.05% Tween)] was applied to the membrane at room temperature for 1 
hour. The diluted primary antibodies (rabbit anti-human BST-2, diluted 1:5000 in 10% 
FBS in 1x TBST) were added to the blot. The blot was incubated at room temperature for 




in room temperature. The diluted secondary antibodies (goat anti-rabbit HRP-conjugated 
antibodies, 1:10000 dilution in 5% nonfat milk and 1x TBST) were added to the blot, and 
incubated at room temperature for 1 hour on a rocking platform. The blot was washed 
briefly with 1x TBST, and then washed with 1x TBST for 15 minutes in room 
temperature. The enhanced chemiluminescence (ECL) Western blotting detection system 
was added to the blot and visualized with the Fujifilm LAS-3000 Imager for 
chemiluminescence detection. For the GAPDH detection, the blot was stipped of the 
bounded BST-2 antibodies. After the ECL detection, the blot was incubated in a stripping 
buffer (100 mM 2-Mercapoehanol, 2% SDS, 62.5 mM Tris-HCl (pH=6.7) at 50°C for 30 
minutes. The blot was washed two times at 10 minutes with 1x TBST in room 
temperature. The blot was then blocked and probed with rabbit anti-human GAPDH 
antibodies (diluted 1:5000 in 10% FBS in 1x TBST) as described above. 
 
4.3 Results  
4.3.1 The primer-template aptamer is a potent inhibitor to HIV-RT in vitro 
Our lab developed a unique SELEX-based technique for selecting primer-
template sequences that bound HIV-RT with high affinity (42). The selected sequences 
bound RT with at least 10-fold tighter binding than the starting material. This was the 
first time a strong sequence preference for specific primer-templates with a DNA 
polymerase was demonstrated. Each of the selected DNA-DNA primer-templates 
resembled the HIV polypurine tract (PPT) in that a run of 6-8 G’s was present at the 3′ 
end of the aptamer isolated, and the run of Gs are critical for tight binding to RT. The 





Figure 4-1: Sequence, structure, Kd, and ∆G values of the various single stranded 
loop-back constructs. Structures were predicted using mfold (80 mM NaCl, 6 mM Mg2+ 
at 37°C) (197). Figure 4-1A showed a modified version of the selected aptamer with 
phosphothioate nt, denoted in asterisks (*). The DNA sequences in Figures 4-1B to D 
were controls with a similar DNA hairpin loop structure. Nucleotides in gray represent 
important changes to 37 NT SELEX (Figure 3-1). The Kd values are averages (number of 
experiments in parentheses) from independent experiments ± standard deviation values 




possible while retaining tight binding and potently inhibiting RT (43). The designed 
primer-template like inhibitor, 37 NT SELEX had a Kd value of 0.66 ± 0.16 nM (see  
Chapter 3, Figure 3-1B for details) (43).  
A potential problem with nucleic acid inhibitors as therapeutics is their 
susceptibility to nuclease attack in the cell. Phosphothioate nucleosides are modified with 
the 5′- phosphate replaced by a sulfur atom to resist cellular degradation. The modified 
aptamers have been used successfully by others with DNA oligonucleotides designed as 
HIV inhibitors (51, 104, 110, 116). Since single stranded regions of nucleic acid are 
particularly susceptible to nucleases, our lab designed a 38 nt aptamer with its three 5′ 
nucleotides and three loop nucleotides replaced by phosphothionucleosides (Figure 4-
1A). The double-stranded loop portion of this aptamer is identical the 37 NT SELEX 
aptamer (Figure 3-1B) while the loop is composed of phosphothioate thymidines rather 
than adenosine residues. An additional phosphothioate thymine was also added to the 5′ 
end. The Kd value (0.28 ± 0.14 nM) indicated tight binding of the aptamer to HIV-RT. 
To test for structural importance of the SELEX aptamers, three control substrates 
with a similar flipback structure were also tested (Figure 4-1B, C and D). Figure 4-1B 
represents a control in which the nucleotides in the stem portion of 37 NT SELEX were 
scrambled, while Figure 4-1C show a similar sequence, while retaining a similar ∆G 
(folding energy) to the designed aptamer. A ~400-fold increase in Kd was observed for 
both controls. These controls varied in the degree decrease in affinity, but both showed 
weak binding compared to 37 NT SELEX. Thus, there was no correlation between 
structural stability (∆G) and affinity (Kd), therefore the binding to RT was driven by the 






Figure 4-2: Sequence and structure of the various linear single-stranded DNA 
constructs. The structures shown were predicted with the DNA mfold program using 
default conditions (80 mM NaCl, 6 mM Mg2+ at 37°C) (197). Names include the length 
in nts of each DNA and the nature of the random sequence. The 37 NT Linear control is a 
single-strand DNA with low structure (∆G = -1.17 kcal/mol). The 37 NT Random 




were flipped without significant alterations to the ∆G values (~ -19 kcal/mol). The G-C 
Flip control showed a ~80-fold decrease in affinity for RT compared to 37 NT SELEX. 
To investigate if the structure or the sequence of the designed aptamer played a 
role in the HIV-1 inhibition, two control DNA oligos with low structures were 
constructed. The 37 NT Linear control is a single-strand DNA with a linear structure and 
a weak stem loop (Figure 4-2A). The 37 NT Random Control is a single-stranded DNA 
that retain the first five nts at the 5′ end and the thymidine loop (Figure 4-2B). However, 
the 37 NT Random Control contains a completely random sequence in the helical region, 
thus the sequence is unlikely to form a primer-template structure with a hairpin loop. 
 
4.3.2 The aptamers do not have a significant affect on cell growth 
Any cellular insult, physical or chemical, most often results in activation of a 
cellular pathway, sometimes resulting in either necrosis or programmed cell death. The 
ability of an antimicrobial agent to cause this effect in the very cells it is supposed 
toprotect is loosely termed cell toxicity. Nucleic acids, especially CG-rich sequences 
have been known to activate Toll-like receptors in host cells leading to the production of 
proinflammatory cytokines (178, 179), and inhibition of cell proliferation (33, 34, 148).  
To study the effects of the aptamer and controls (Figures 4-1 and 4-2) in cell 
proliferation, the CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega Inc.) was used. This kit is a colorimetric assay to measure the amount of 
NADPH or NADH produced in proliferating cells. The NADPH or NADH turns the MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium), which is yellow in color, to a purple formazan compound (Figure 4-3). The 






Figure 4-3: Structures of MTS tetrazolium and its formazan product. The MTS 
tetrazolium compound, which is yellow in color, is reduced by cells into a purple-colored 
formazan product that is soluble in tissue culture medium (35). This conversion is 
presumably accomplished by NADPH or NADH produced by dehydrogenase enzymes in 




the aptamer and controls at any of the concentrations used (0, 0.5, 1, 2, and 4 µM) did not 
have a significant affect on Jurkat E6-1 cell growth over a 48 hour growth period (Figure  
4-4). Similarly, the 38 NT Thioaptamer and 37 NT Arbitrary Control both did not have a 
significant effect on cell growth when monitored with the trypan blue dye exclusion 
method (Figure 4-5). 
 
4.3.3 All structured aptamers show significant inhibition to HIV-1 infection 
HIV-1 viral replication was examined in Jurkat E6-1 cells with various 
concentrations of the Thioaptamer and several aptamer controls (see Figure 3A-F and 
(43)). For these experiments, all the flipback controls were also modified with 
phosphothioates in the loop and 5′ tail region. It is important to note that for the in vitro 
Kd assays, which required nucleotide addition by HIV-RT, the flipback aptamers had a 
dG at the 3′ end. In the cellular inhibition assays the 3′ dG was replaced with ddG using 
Klenow polymerase (see Methods). This was done to prevent extension of the aptamers 
which would have resulted in blunt-ends and a loss of affinity for RT (43).  
In the cellular assays, no carrier for transfection was used to aid entry of the aptamer into 
cells; previous studies had shown that some DNA aptamers at high concentrations can 
enter cells without transfection (110, 111, 116). To measure the infectivity of the virus in 
the presence of various concentrations of different aptamers, the TCID50/ml (tissue 
culture infectious dosage, of 50% of the cell population) of the Jurkat cells were 
measured using a p24 ELISA antigen capture assay or TZM-bl reporter cells (Figure 4-6). 
The measurement of TCID50/ml was based on a limit-dilution assay, which quantified the 





Figure 4-4: Cell proliferation in Jurkat E6-1 cells in the presence of various 
concentrations of the 38 NT Thioaptamer and the control DNAs. Cells were 
incubated with 0.5, 1, 2 and 4 µM of the 38 NT Thioaptamer and various aptamer 
controls for 48 hours at 37°C, 5% CO2. The MTS tetrazolium compound (from Promega) 
was added to the Jurkat cells and incubated for 48 hours at 37°C, 5% CO2. The 
absorbance values (at 450 nm) were averages from three independent experiments. The 










Figure 4-5: Jurkat E6-1 cell count in the presence of various concentrations of the 
38 NT Thioaptamer and 37 NT Arbitrary Control. Cells were incubated with 0.5, 1, 2 
and 4 µM of the 38 NT Thioaptamer and 37 NT Arbitrary Control for 10 days at 37°C, 
5% CO2. The starting concentration of the Jurkat cells were at 1 x 10
5 cells/ml. Typically 
Jurkat cells double in ~24 hours and can reach densities of ~3 x 106 cells/ml. Cell growth 






Figure 4-6: TCID50/ml values of Jurkat E6-1 cells infected by HIV-1 LAI virus, with 
various concentrations of the 38 NT Thioaptamer and its controls. Cells were 
incubated with 0, 1, 2 and 4 µΜ of the 38 NT Thioaptamer and various aptamer controls 
after the adsorption of HIV-1 at 37°C, 5% CO2. Time points used in the infection were 5, 
6 and 7 days post infection. Cell-free media collected from the various times were used to 
infect Jurkat cells for 5 days in a limit-dilution assay. The TCID50/ml values were based 
on the calculations with the p24 antigen capture assays for evaluating the limit-dilutions 
from the various aptamers. The TCID50/ml values were averages from two independent 




TCID50/ml level between days 5 and 6 post infection, and further increase of TCID50/ml 
to a peak level between days 6 and 7, indicating the virus was infecting the Jurkat cells 
and producing infectious virus. All the hairpin loop aptamers (Figure 4-1) resulted in a 
significance decrease in infectious virus production, even when only 1 µM of aptamer 
was present, and a further decrease with 4 µM aptamer. In contrast, both 37 NT Linear 
Control and 37 Random Control (Figure 4-2) did not show any decrease in the TCID50/ml 
level, indicating the low structure DNA did not have an effect in HIV replication in the 
Jurkat cells.  
 
4.3.4 Effect of HIV-1 on aptamer entry into Jurkat cells  
Since no carrier was used to aid entry of the aptamer into cells, we examined 
entry of the aptamer into Jurkat cells in the presence or absence of fluorescently-tagged 
(with fluorescein) Thioaptamer. Figure 4-7 shows representative panels generated by 
epifluorescence microscopy, which demonstrates the increase in the amount of aptamer in 
cells in the presence versus the absence of HIV virus infection. Results quantifying cell 
entry of the aptamer are shown graphically in Figure 4-8. No fluorescent label was 
observed at 0 or 0.5 µM aptamer (data not shown). At 2 µM aptamer approximately 50% 
of the cells showed the green fluorescence signal in the presence of virus, while very few 
cells showed the fluorescein signal in the absence of virus. This is consistent with 
previous studies by Metifiot et al. (111). At 4 µM about 70% of the cells showed the 
presence of the fluorescein signal in the presence of virus. Note that over 50% of the cells 
were fluorescently labeled even without the virus. A general observation was that the 





Figure 4-7: Entry of the aptamer into Jurkat cells visualized in the presence or 
absence of fluorescein-tagged 37 NT Thioaptamer. Jurkat cells were infected at MOI = 
0.1 or mock infected with PBS. At 48 hours post infection, cells were washed three times 
with 1x PBS, fixed in 4% formaldehyde, and then analyzed using an epifluorescnce 
microscope. Cells were stained with DAPI to identify the nucleus. The panels with 
aptamer were not meant to reflect the proportion of the cells that contained the 










Figure 4-8: Graph showing the quantification of fluorescein-tagged 37 NT 
Thioaptamer cell entry in the absence or presence of HIV-1. A total of 40 cells in 
each sample were counted, and each cell that contained the fluorescein signal was 
counted as a positive. Cells were infected, fixed, and stained as decribed in Methods and 




presence of virus.  
 
4.3.5 The aptamers did not induce BST-2 production in cell culture 
To investigate if 38 NT Thioaptamer induces interferon production which in turn 
upregulates BST-2 expression, the 38 NT Thioaptamer and a primer-template construct 
(37 NT ∆G control) were used in cells for analysis of BST-2 expression. The aptamers 
were incubated with Jurkat cells, HEK 293 cells (both Jurkat and 293 cells are BST-2 
inducable) and TZM-bl cells (a HeLa cell derivative; HeLa cells constitutively express 
BST-2). The cell lysates were subjected to SDS-PAGE, and BST-2 was detected by 
western blotting probed with an anti-BST-2 primary antibody and a horseradish 
peroxidase-conjugated secondary antibody. The various cell lines showed very similar 
expression of BST-2 when detected on an immunnoblot, regardless of the presence or 
absence of the aptamers (Figure 4-9). Note that BST-2 is expressed as multiple bands 
between 25–35 kDa on an SDS-PAGE due to protein being heterogeneous glycosylated 
(100). The TZM-bl cell samples had an extra glycosylated band at ~30 kDa, however it is 
still somewhat surprising that the overall BST-2 expression level was similar to the BST-
2 levels in 293 and Jurkat cells and not higher, due to the constitutive expression of BST-
2 in this cell line. 
 
4.4 Discussion  
4.4.1 Effects of primer-template apatmers on cell proliferation 
Previous studies have shown that the DNA primer-template aptamer developed by 






Figure 4-9: Effect of 38 NT Thioaptamer and 37 NT ∆G control on BST-2 
expression in various cell lines. Jurkat E6-1 clone cells, HEK 293 cells and TZM-bl 
cells were pretreated with 0 or 2 µM 38 NT Thioaptamer and 37 NT ∆G control for 48 
hours at 37°C. Cells were lysed in 2X Laemmli buffer [4% SDS, 125 mM Tris-HCl 
(pH=6.8), 10% 2-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue] at 95°C. 
Levels of BST-2 expression were determined by western blotting using anti-BST-2 
antibody. The expression of the GAPDH was also measured by probing the blot to anti-
GAPDH antibodies. The different cell lines have various level of GAPDH expression 





aptamer could inhibit HIV replication in cells. To show that the aptamer can effectively 
inhibit HIV replication, it was important to establish that there was little or no cellular 
toxicity at concentrations where viral inhibition occurred. Other studies had shown 
nucleic acids and aptamers in cell media at concentrations in the low micromolar range 
had little or no toxicity (131). The designed thioaptamer and controls did not alter cell 
proliferation in a 48-hour period (Figure 4-4), and the trypan blue cell exclusion 
monitoring over a 10-day period (Figure 4-5) both indicated the cells had a normal cell 
growth rate. Note that even the cells were dividing normally in the presence of the 
aptamers, a cell proliferation assays should be performed in the same time course (up to 7 
days) as the infection assay. Also, even the cells can proliferate at a normal rate, even 
when cellular responses are elicited by external factors. Therefore the level of cell 
proliferation does not necessarily reflect specific changes in the internal cellular 
environment, some of which could alter virus replication. Some oligonucleotides, most 
notably those that can form G-quartets and other GC-rich oligos, have been reported to 
have effects on cells ranging from induction of senescence and aging (141) to inhibition 
of proliferation (33, 34, 148). 
 
4.4.2 The possible roles of the structure of the primer-template aptamers to HIV-1 
inhibition in cell culture 
The thioaptamer and the flipback control aptamers (Figure 4-1) showed 
comparable inhibition of HIV replication in Jurkat cells. In contrast, the low-structure 
DNA controls (Figure 4-2) had no effect on HIV replication. This suggests that the 




there were no effects on cell proliferation and no cell toxicity, the structured oligos most 
likely either induced activation of specific cellular pathways, or directly interacted with 
cellular proteins required for HIV replication, or interacted with viral proteins to inhibit 
replication. Since all the structured oligos including the thioaptamer formed primer-
template configurations, it is possible that they bound to RT and inhibited replication. 
Since the flipback controls used here bound with low affinity to RT in vitro (43), it seems 
unlikely that they would have comparable inhibition to the tight binding thioaptamer in 
cells. However, a ddG terminated version of the 37 NT ∆G Control showed much greater 
inhibition in the in vitro RT extension assays than was expected from the Kd 
measurement (43). A possible reason for this is formation of a “dead-end complex” when 
the chain-terminator is present. Dideoxy terminated primer-templates bind with a very 
long half-life to HIV-RT in the presence of the template-directed dNTP that follows the 
dideoxy moiety (170). This effect may be observed in the cells where dNTPs are present. 
In effect, the presence of a dideoxy nucleotide at the 3′ terminus of all the flipback 
inhibitors used here could have made them more effective RT inhibitors in the cell. In 
order to test the possibility of the flipback oligos inhibiting RT in cells we attempted 
unsuccessfully to isolate revertants that could grow in the presence of the thioaptamer. 
Presumably this could have occurred through RT mutations that allowed the ddG to be 
excised so that the oligos could then be extended. In this case changes in RT that 
decrease binding to the oligos, which may not have been possible, would not have been 
necessary to overcome inhibition.   
In the future, it will be more advantageous to utilize the TZM-bl cell line to 




designed to allow single-cycle HIV infection, which single-cycle infections would allow 
more precious measurement on the step(s) in HIV replication the aptamers have an 
inhibition effect. The quanitification process will also be more direct, which the viral 
levels will be measured by the luciferase activity in the TZM-bl cells. 
It is known that highly structured nucleic acids can elicit innate immune responses 
in cells (70). In addition to activation of cellular pathways through Toll-like receptors 
(132), presumed binding to cellular proteins including ribosomal protein L7a (143), 
nucleolin (41, 62), elongation factor 1A (eIF1A) (19, 38, 59), STAT3 (170), and growth 
factors (18) have been reported. It is notable that GC-rich oligonucleotides and those that 
can form G-quartets are most associated with inhibitory cellular properties. None of the 
flipback aptamers used here inhibited proliferation at the concentrations used. However, 
proliferation assays were done in the absence of viral infection and under these 
conditions entry of the oligos into the cells was reduced (Figures 4-4 and 4-7). Attempts 
to investigate toxicity by transfecting the oligos into cells were inconclusive because 
Jurkat and other T cell lines transfected poorly (data not shown). Transfection reagents 
that improved delivery efficiency (specifically N-TER Nanoparticle siRNA Transfection 
System from Sigma-Aldrich, Inc.), also inhibited virus infection even in absence of 
oligos and were not pursued for the purpose of delivery. Therefore it is unclear if the 
flipback, or even the low structure controls would alter cell proliferation if a higher 
concentration had entered the cells. With respect to the nature of the oligos used here, the 
Thioaptamer, though not particularly G rich (12 out of 38 of the nucleotides are Gs), was 
highly structured and had a high GC content (24 out of 38). Other flipback controls were 




possibility of interference or alterations of cellular functions that lead to HIV inhibition 
cannot be dismissed.   
 
4.4.3 Possible relationships of the aptamer uptake and the presence of HIV-1 
Since the assays to measure cellular uptake were conducted over a short 48 hour 
period, a higher MOI (0.1 vs. 0.01 for assays measuring aptamer inhibition) was used to 
provide more viral particles for more pronounced effect on visualization of the cells. 
Even in the presence of virus it took at least 2 µM of the labeled thioaptamer to visualize 
aptamer uptake. Aptamer entry in the absence of virus did occur, however it took twice 
the amount of oligo (at 4 µM) for ~ 50% of the cells to show the fluorescent signal. Since 
the threshold for observing a signal is not known it is possible that lower levels of 
aptamer entered cells even in the absence of virus and below the 2 µM oligo 
concentration. Some inhibition of virus replication was observed at 1 µM oligo (Figure 4-
6) despite no apparent entry of the aptamers into cells based on the cell uptake assay (data 
not shown). This suggests that the aptamer may enter the cell but does not overcome the 
threshold for visualization. In the future, bright field microscopy will be performed on the 
Jurkat cells to locate the cell nucleus, and its relation to where the fluorescent signal is 
located in the Jurkat cell. It is possible that inhibition could be at the level of virus entry. 
The role of the aptamers in viral entry could be investigated using VSV-G pseuodtyped 
HIV virus (44, 140). These viruses, which use the VSV-G protein to gain entry, are 
typically much less susceptible to entry blocks. If the virus does facilitate aptamer entry 
into cells, the virus chaperoned uptake may be size specific; less aptamer was required 




Aptamers used by Metifiot et al. also formed G-quartet structures which could have 
influenced uptake. Other groups have observed virus chaperoned uptake of unrelated 
larger nucleic acids (>50 nt) suggesting that this may be a general phenomena (110).  
 
4.4.4 The effects of aptamers on cellular pathways induction and HIV inhibition 
BST-2 was identified as an IFN-inducible host factor in cells (120), where 
interferon production was induced by viral infection or by nucleic acids. Even though the 
aptamer at low micromolar concentrations did not induce a higher level of BST-2 
production, there are a couple of possibilities concerning the role of the aptamers in 
cellular pathway induction. BST-2 is relatively stable on the surface of cells, with a half-
life of ~8 hours (158), however the aptamer may play a role in blocking the synthesis of 
the new BST-2 molecules, especially if the aptamer also induce other cellular factors. 
Even though the level of BST-2 expression was similar with or without the presence of 
the aptamers, other host cell pathways (such as innate immunity responses) could be 
activated. Some of the future experiments to determine what factor(s) may play a role in 
the aptamer inhibition include ELISAs for interferon alpha (IFN-α) detection, caspase-
3/7 assay to study possible effects of programmed cell death, or TLR3 / TLR9 expression 
to observe if the aptamer is inducing any toll pathways. 
 
4.4.5 Conclusion and future directions 
Overall the above results demonstrate inhibition of HIV replication using high 
concentrations of flipback nucleic acids in Jurkat cells. Replication inhibition did not 




was a better inhibitor of RT in vitro and bound to RT with much greater affinity than the 
other flipback oligos (43), was not a more effective inhibitor (Figure 4-6). Many 
questions, in particular, how the oligos inhibited replication, were left unanswered. Some 
relatively straight forward experiments could have been performed to rule out some of 
the possibilities. For virus entry could be investigated using VSV-G pseuodtyped HIV 
virus (see section 4.4.3 for details). Specific steps in the replication process (1st and 2nd 
stand DNA synthesis) could be evaluated using real-time PCR (124), integration using 
Alu-PCR (144), processing of viral proteins using radioimmunoassays (3), and budding 
of the virus from the cells using scanning electron microscopy (86). These experiments 
would have helped to home in on the step(s) of virus replication that were affected by the 
oligos. Based on previous results, the non-specific nature of the inhibition, and the high 
concentration of oligos required for inhibition, there was a high likelihood that inhibition 
was caused by activation of a cellular response, or non-specific interference with virus 
entry. Such a finding would add little to the current understanding how cells respond to 
nucleic acid treatment or whether the aptamer was a good model for further development 
as an HIV inhibitor. Because of this and time limitations, the above experiments were not 
pursued. These experiments would be much more worthwhile for an aptamer with 
demonstrated specificity.  
One clear problem with this work was the inability of the oligos to gain entry into 
the cells without adding large concentrations to the medium. There are several methods 
available to transfect cells with oligonucleotides. In addition to the N-TER reagent 
described above, vector-assisted delivery methods using liposome vesicles are another 




surrounded by a phospholipid bilayer. The aptamer is either enclosed inside the aqueous 
core or complexed to the phospholipids of the liposome (51, 104, 110, 116). The aptamer 
enters the cells by fusion of the liposome vesicle and the cell membrane. Adding a 
lipophilic moiety or cell penetrating protein (HIV Tat protein or Antennapedia penetrin 
protein for example) to the oligos is another possibility (84). These have been shown to 
improve the entry of nucleic acids including aptamers, siRNAs and antisense RNAs (171, 
174). Attaching the oligos to HIV envelope-specific aptamers that bind to the virus and 
can cargo other nucleic acids into the cell is another method which has shown some 
success for aiding siRNA entry (192). To be effective, the delivered aptamer must not 
only enter the cell and remain intact, it must reach a high enough concentration to inhibit 
replication and gain access to the replication complex. Aptamer based therapies that 
target extracellular proteins have already been demonstrated in practice (see “Macugen” 
in Introduction) and will likely expand rapidly. Those targeted against intracellular 






Chapter 5: General discussion 
Aptamers are a powerful tool in developing various biosciences applications, as 
well as understanding the mechanistics of protein-nucleic acid interaction (82). There are 
already various classes of DNA and RNA aptamers for HIV being developed and studied 
(Chapter 3) (7, 39, 71, 95, 112, 149), however to gain a better understanding on HIV 
replication, and to develop novel techniques for facilitating the continuing discovery for 
alternative drug therapy. 
The main goal of this dissertation focuses on the study of two different classes of 
HIV-RT aptamers: (1) to develop and characterize a unique primer-free SELEX aptamer 
and (2) to investigate the effects of a previously isolated primer-template HIV-RT 
aptamer on HIV-1 infection in cell culture. In chapter 2, I introduced a novel primer-free 
SELEX technique on selecting aptamer targeting HIV-RT. The only other HIV-RT 
aptamer selected from a similar method (minimal primer SELEX) was developed by 
Joshi and Prasad (87). In primer-free SELEX (or minimal primer SELEX), the main goal 
is to eliminate the biases from the flanked regions present in the random sequences 
selected from traditional SELEX. Primer-free SELEX techniques usually requires 
hybridization and enzymatic steps to regenerate the flanked regions for PCR 
amplification (126, 127, 184), which required more time and resources for each round of 
the SELEX process. However, the reduction of biases may outweigh the added effort to 
select for random sequences directly interacting with their targets.  
In my primer-free SELEX technique, Themostable RNA ligase was used for 
streamlining the primer-SELEX process. However, there were some limitations posed by 




disfavored a G at the 3′ end (102). In future selections, a random pool of sequences with a 
T at the 3′ end will be used to increase the efficiency of the selection process. 
Thermostable RNA ligase showed reduced efficiency in the ligation of DNA sequences 
with very high structures, but oligos with some secondary structures ligated with 
efficiency comparable to low structure DNA (Chapter 2, Figure 2-5) (102). Surprisingly, 
with two separate SELEX experiments a set of sequences almost identical to each other 
and with arrangement of four guanosine doublet was selected (102). The selected aptamer 
(PF1) bound ~10 fold tighter than the starting material. Chapter 3 focused on 
understanding on PF1 and the factors contributing to PF1’s high affinity to HIV-RT. Two 
different classes of HIV-RT aptamers were compared with PF1 on their ability to inhibit 
RT extension: (1) G-quadruplex aptamers (R1T and S4) (112), and (2) a primer-template 
apatmer developed from our lab (37 NT SELEX) (42, 43). 
PF1’s binding ability to HIV-RT was affected by the central diguanosine repeats, 
length, and the nucleotide arrangement. Even though the guanosine motifs are found in 
DNA sequences that form an intramolecular G-quadruplex (Chapter 3) (108), CD 
analysis indicted that PF1 did not form a G-quadruplex (Figure 3-9). It is still unclear yet 
how exactly the diguanosine repeats and the length played a role in terms of the 
conformation of the aptamer. The DNA mfold analysis of PF1 indicated that it has very 
low structure (Chapter 2), and RT tended to have a lower affinity towards unstructured 
nucleic acids (see below). However, it is possible that interaction between HIV-RT and 
PF1 may induce a change in the conformation of the aptamer leading to a higher 
secondary structure, or G-quadruplex formation. To evaluate if PF1 forms a more 




analysis using NMR or X-ray crystallography would be needed. It is possible to measure 
the CD spectrum of PF1 with HIV-RT; however the presence of the protein would 
interfere with the spectrum, since both the nucleic acid and protein are measured in a 
similar range in terms of wavelength. This would make interpretations more difficult. 
Consistent with previous results, both the G-quadruplex aptamers and the primer-
template aptamers are potent inhibitors to HIV-RT extension in vitro. The inhibition is 
due to their ability to directly bind to the RT active site and block the access of the HIV-
RT to the substrate. Even though PF1 had a relatively lower inhibitory effect compared to 
the other aptamers, it still showed 50% inhibition at a concentration approximately equal 
the substrate concentration in the inhibition reaction. This suggests that PF1 binds about 
as tightly as the primer-template used in the assays. Such tight binding would not 
normally be seen on a 30 nt single stranded DNA with very low predicted structure. It has 
been speculated that PF1 does contain some secondary structure, and the length of PF1 
might be at the limit of the minimal length where a single-stranded DNA can bind tightly 
to HIV-RT. It would be interesting to use the same primer-free SELEX method and select 
for DNA aptamers to HIV-RT with different lengths (both longer and shorter than 30 nt).  
These aptamers could then be analyzed to see if they enhance binding to HIV-RT, and/or 
whether the same diguanosine repeats would still be selected. 
The selection of single-stranded DNAs from this unique primer-free SELEX 
technique can be utilized in development of aptamers for other HIV enzymes, or for any 
protein targets. It has potential for development of small molecule-based therapy, 
especially with the coupling of a delivery system (see below). Aptamers developed using 




One main consideration however is that the in vitro analysis of the aptamer does 
not necessarily translate to the interaction between the oligo and the virus in a cellular 
system. In chapter 4 I focused on studying the effects of the primer-template aptamer 
developed by our lab (37 NT SELEX) on HIV-1 replication in cell culture. The 37 NT 
SELEX was modified with thiophosphate at the 5′ end and the loop structure to prevent 
degradation of the oligo in the cell (“thioaptamer” in chapter 4). Previous studies have 
shown that highly structured nucleic acids have a tendency to activate innate cellular 
responses (70). Even though the designed thioaptamer and its structured controls did not 
decrease cell proliferation, the effects of the oligos on the host cell response might 
interfere with the HIV infection process (see below) (69, 162).  
The thioaptamer and control aptamers with higher structure (Figure 4-1) all 
showed HIV inhibition in cell culture. The thioaptamer, while effective at curbing HIV 
replication, did probably did not achieve inhibition through the aptamer binding to HIV-
RT as other structured controls that bound RT with much lower affinity were equally 
inhibitory. One of the possible steps that the aptamer inhibits HIV replication is at the 
entry stage, and there are compounds that block HIV-1 cell entry (180). The inhibition by 
structured DNA also pointed to the possibility that the thioaptamer blocks viral 
replication via the induction of specific cellular pathways, or other direct interactions 
with cellular proteins required for HIV replication. Double stranded nucleic acids are 
known to activate cellular pathways through Toll-like receptors (132), or to induce 
interferon production, which downregulates host factors induction, such as tetherin (BST-
2) which prevents HIV-1 from budding out of the cell (8). Even though the aptamer at 2 




contributing to the HIV inhibition. Some of the possible candidates for investigation 
included a more direct measurement of interferon levels (via ELISA against IFN-α or 
IFN-γ), or the caspase-3/7 assay to study on the effect of programmed cell death. 
Cell-based analysis on PF1 and its variants will be the next logical step for 
investigating how PF1 affects HIV replication in cell culture. The lower structure and 
shorter oligo length provide some advantage for PF1 in future cell culture studies. For 
both PF1 and 37 NT SELEX aptamers, one of the barriers to overcome is the delivery of 
the oligo into the cell. An effective aptamer delivery into the cell lowers the aptamer 
dosage required for inhibition, and may reduce the cytotoxic effects and host responses. 
Vector-assisted delivery methods using liposome vesicles are one of the alternative 
methods for aptamer delivery (51, 104, 110, 116), where the nucleic acid enters the cells 
by fusion of the liposome vesicle and the cell membrane. Note that such delivery 
methods must not elicit any host response or be toxic to host cells. Recent reports have 
showed that DNA aptamers can be modified to form a self-assembled aptamer-micelle 
nanostructures, and have low cytotoxicity (187). However, the ability of the modified 
aptamer-micelle particles to inhibit HIV replications in cells has not been assessed. 
Aptamers facilitate the understanding of HIV-RT properties, and its interaction 
with different types of nucleic acids. A diverse range of SELEX approaches provide the 
tools for generating different classes of aptamers, where each has their own unique 
features for various applications. With the in vitro and cell-based analysis, aptamer 
development aids the discovery of new and exciting ways to learn more about HIV 
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